Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 20 22
Confidential Page 2of 74Investigator  Statement
I have read this protocol and understand its requirements. I agree to conduct the study as 
described herein and will not deviate fro m the protocol without pri or wri tten approval  from the 
sponsor or designee. Any protocol  changes must be made by written amendment to the protocol 
and will not be implemented until approved by the inst itutional review board or ethi cs 
committee.
Principal Invest igator Signature Date
Printed Name
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 20 22
Confidential Page 3of 74Protocol Amendment Summary of Changes 
DOCUMENT HISTORY
Document Date
Amendment 4 31Oct2022
Amendment 3 27 Sep 2016
Amendment 2 25 Jun 2012
Amendment 1 24 Nov 2010
Original Protocol 01 Sep 2010
Amendment 4 ( )
The purpose of Global Protocol Amendment 4 is to incl ude administrative change, to update 
recent changes in Sponsor Contact and Medical Contact/T AMD for the study and informat ion on 
the Contact Page updating email and phone number to address Safe ty concerns.
The fo llowing i s a summary  of changes made in Glo bal Protocol Amendment 4. Strikethrough 
text denotes text removed and bo lded text denotes added text. Addit ional administrative edits 
were al so m ade, but not specifically noted (eg, corrected sp elling, punctuation, grammar, 
abbreviat ion, and st yle errors) including global edits required for consistency .

Oxybutynin Chloride 10% Gel AbbVie Inc .
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 7of 74Protocol Section(s) Description of Changes Rationale for Changes
Immediate Reporting of Serious 
Adverse Events and Events of 
Special InterestUpdated changes in reporting SAE under section 9.7.1.5.
Following information is removed
Fax the SAE Form for Clinical Trials to Allerg ann Sales, LLC .
Global fax number for SAE or Pregnancy Reporting: 
1-714-796-9504 (backup fax 1 -714 -246-5295)
or email it to IR -Clinical -SAE@ allerg an.com.
In case of fax failure or the site does not receive confirmation of receipt of the fax, the 
site must email the report to IR-Clinical -SAE@ allergen .com .
Added the foll owing information
Fax the SAE Form for Clinical Trials to AbbVie Inc.
Global fax number for SAE or Pregnancy Reporting: 
1-714-796-9504 (backup fax 1 -714 -246-5295)
or email it to IR -Clinical -SAE@ abbvie .com.
In case of fax failure or the site does not recei ve confirmation of receipt of the fax, the 
site must email the report to IR -Clinical -SAE@ abbvie .com.To reflect current information
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 9of 742 SYNOPSIS
Sponsor:
AbbVie Inc.
Name of Finished Pr oduct:
oxybut ynin chloride gel
Name of Active Ingr edient:
oxybut ynin chloride
Study Title:
A Two-part, Multicenter, Dose -titration Study  Evaluating the Efficacy , Safety, 
Pharmacodynamics, and Pharmacokinet ics of Oxybut ynin Chloride 10% Gel  for the Treatment 
of Detrusor Overactivit y Associated Wit h a Neurological Condit ion in Pediatric Patients
Study Number:
OG09002
Study Phase: Phase 4
Two-part Study :
This study  will be conducted in 2 parts, Pre -Amendm ent 3 and Post -Amendment 3, as fo llows:
Pre-Amendment 3: A doubl e-blind, rando mized, placebo -controlled treatment study  with 
open -label extensio n. Pati ents will  be enrolled into the 6 -week pl acebo -controlled 
treatm ent followed by an 8- week open -label treatment phase.
Post
-Amendment 3: An open -label treatment study . Pati ents will  be enrolled in a 6 -week 
open -label treatment phase. A porti on of  enrolled pati ents will  receive an addi tional 
8weeks of open -label treatment for a total of 14 weeks of open- label treatm ent.
Primary Objectives:
The primary  object ives are:
Pre-Amendment 3: T o eval uate the efficacy  of daily  treatm ent wi th oxybut ynin chloride 
gel com pared to pl acebo in pediatric patients during the first 6 weeks of a 14- week 
treatm ent peri od.
Post-amendment 3: T o eval uate the efficacy of daily treatment with ox ybutynin chloride 
gel in pediatri c pati ents during the first 6 -weeks of a 14 -week open -label treatm ent 
period.
Secondary Objectives ( for Pre -Amendment 3 and Post -Amendment 3):
The secondary  objectives are to evaluate the pharmacokinet ics, pharmacodynamics, safet y, and 
skin tol erabilit y of oxybutynin chloride gel in pediatric patients.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 10of 74Study Design:
This study  was init iated as a double -blind, pl acebo -controlled study  with an open -label 
extensio n, and amended to enroll pat ients under only open -label treatm ent. Pri or to Amendment 
3, pati ents aged 6 years to < 17 y ears were rando mly assigned 1:1 to receive double -blind 
oxybut ynin chloride gel or placebo gel for 6 weeks, fo llowed by a n open -label, 8 -week peri od to 
generate safet y data. All patients began treatment with 0.75 g of gel/day for 2 weeks. Patients 
then returned to the clinic for a potential dose titratio n and at this time their dose could have been 
adjusted up to 1 g/day , down to 0.5 g/day , or rem ained the same at 0.75 g/day . The determinat ion 
of dose was based on the invest igator ’s clinical judgment and assessment of the patient ’s bladder 
symptoms and treatment side effects. Dose titration was permitted only once during the entire 
6-week double -blind, pl acebo -controlled period. Patients continued blinded treatment for 
4additional weeks unt il the end of the double -blind treatment period.
Post
-Amendment 3, the study dose -titration study  in pediatri c pat ients, ages 3 y ears to 
< 17 years, wi th detrusor overactivit y associ ated wi th a neuro logical condi tion. Efforts will be 
made to enroll a greater number of patients fro m the ages of 3 y ears to < 6 y ears. Pati ents m ust 
be suitable candidates for anticho linergic therapy and must be using clean intermittent 
catheterizat ion (CIC) for bladder control. The study will include a screening period fro m Day -13 
to Day  -5 and a 14 -week open -label treatm ent period. The expected duration of the study  for 
each patient will be up to 16 weeks. No c hanges were made in the starting dose, compared to the 
Pre-Amendment 3 study  design, in that all pat ients will begin treatment with 0.75 g of gel/day  
for 2 weeks. Patients will then return to the clinic for a potential dose titration and at this time 
theirdose m ay be adjusted up to 1 g/day , down to 0.5 g/day , or rem ain the same at 0.75 g/day , 
depending on individual response and tolerabilit y. The determinat ion of dose will be based on the 
investigator ’s clinical judgment and assessment of the patient ’s bladder symptom s and treatm ent 
side ef fects. Dose titration will be permitted only once during the entire 14 -week treatm ent 
period. Pati ents will cont inue the adjusted dose for 12 addit ional weeks unt il the end of the 
open -label treatment period.
Safety will be eval uated by  monitoring adverse events, physical examinat ions, vital signs, 
clinical laboratory  evaluat ions, skin eryt hema at the applicat ion site, and a visio n symptom  
questionnaire.
Study Population:
Pre-Amendment 3 included pediatric patients, from a ges 6 y ears to < 17 y ears, who had a 
diagnosis of detrusor overactivit y associ ated wi th a neurol ogical condi tion and were using CIC 
to con trol bladder function. These patients were enrolled into the 6 -week placebo -controlled 
treatm ent pl us an 8 -week open -label treatm ent phase of the study . Pos t‑Am endment 3 enrollment 
will include pediatric patients from ages 3 y ears to < 17 y ears, who have a di agnosis of detrusor 
overactivit y associated wi th a neuro logical condi tion and are using CIC to control bladder 
functi on, wi th an enrollment of a minimum o f 25 pati ents. These patients will be enrolled in a 
14-week open -label treatment phase (approximately 10 pat ients are expected to complete the 
14weeks).
Test Pr oduct, Dose, and Mode of Administration:
Oxybut ynin chloride gel , 0.5 g, 0.75 g (starting dose for Pre -and Post -
Amendment 3), or 1 g 
sachets, applied transdermally once daily to dry  intact skin.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 13of 743 TABLE OF CONTENTS
1TITLE P AGE .......................................................................................................................1
Protocol  Amendment Summary of Changes ................................................................................3
2SYNOPSIS ..........................................................................................................................9
3TABLE OF CONTENTS .................................................................................................... 13
4LIST OF ABBREVIA TIONS AND DEFINITIONS OF TERMS ........................................ 17
5ETHICS ............................................................................................................................. 18
5.1 Institutional Review Board or Ethics Co mmittee ....................................................... 18
5.2 Ethical Conduct of Study .......................................................................................... 18
5.3 Patient Inform ation and Consent ............................................................................... 18
5.4 Authori zation to Di sclose Protected Health Information ............................................ 19
6INVESTIGA TOR AND STUDY ADMINISTRA TIVE STRUCTURE ............................... 20
7INTRODUCTION ............................................................................................................. 21
8STUDY  OBJECTIVES ...................................................................................................... 23
8.1 Primary Object ives.................................................................................................... 23
8.2 Secondary  Object ives................................................................................................ 23
9INVESTIGA TIONAL  PLAN ............................................................................................. 24
9.1 Overall Study  Design and Pl an.................................................................................. 24
9.2 Rationale for Study  Design and Control Group ......................................................... 25
9.3 Selection of Study  Popul ation................................................................................... 26
9.3.1 Inclusio n Cri teria........................................................................................... 26
9.3.2 Exclusio n Cri teria.......................................................................................... 27
9.3.3 Patient Identificat ion..................................................................................... 28
9.3.4 Removal of Patients from Treat ment or Assessment ...................................... 28
9.4 Study  Treatments ...................................................................................................... 28
9.4.1 Treatments Administered ............................................................................... 28
9.4.2 Ident ity of Study  Treatment ........................................................................... 29
9.4.2.1 Descript ion of Study Treatment ...................................................... 29
9.4.2.2 Packaging, Labeling, and Dispensing .............................................. 29
9.4.2.3 Storage and Accountabilit y.............................................................. 29
9.4.3 Method of Assigning Patients to Treatment Groups ....................................... 30
9.4.4 Selection of Doses and Timing of Administration in the Study ....................... 30
9.4.5 Blinding ........................................................................................................ 31
9.4.6 Prior and Concomi tant Therapy ..................................................................... 31
9.4.7 Treatment Compliance ................................................................................... 32
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 14of 749.5 Study  Activities......................................................................................................... 32
9.5.1 Screening Period ( 5 to 13 Days ).................................................................... 32
9.5.1.1 Visit A(Screening V isit).................................................................. 32
9.5.2 Open -label Treatment Period (14 W eeks) ...................................................... 33
9.5.2.1 Visit B(Baseline Visit) (W eek 0 of  Treatment) ................................ 33
9.5.2.2 Visit C(Week 2 of Treatment) Dose Titration Opportunit y.............. 34
9.5.2.3 Visit D(Week 6 of  Treatment) ......................................................... 34
9.5.2.4 Visit E(Week 10 of Treatment) ....................................................... 35
9.5.2.5 Visit F (Week 14 of Treatment) or Early Terminat ion...................... 35
9.5.3 Exit/Early T erminat ion Visit .......................................................................... 36
9.5.4 Early T ermination Act ivities.......................................................................... 36
9.6 Efficacy Assessment .................................................................................................36
9.6.1 Urinary  Diary ................................................................................................ 36
9.6.2 Efficacy V ariables .......................................................................................... 36
9.6.2.1 Primary Efficacy V ariable ................................................................ 36
9.6.2.2 Secondary  Efficacy V ariables .......................................................... 37
9.6.2.3 Urodynamic V ariables ..................................................................... 37
9.7 Safety Variables ........................................................................................................ 37
9.7.1 Adverse Events .............................................................................................. 38
9.7.1.1 Causality Assessment ...................................................................... 38
9.7.1.2 Severity Assessment ........................................................................ 39
9.7.1.3 Serious Adverse Event .................................................................... 39
9.7.1.4 Reporting Adverse Events and Serious Adverse Events .................. 40
9.7.1.5 Immediate Reporting of Serious Adverse Events and Events of 
Special Interest ............................................................................... 41
9.7.1.6 Reporting of Pregnancies Occurring During the Study ................. 41
9.7.1.7 Potential Hy ’s Law Cases ............................................................... 42
9.7.2 Clinical Laboratory  Evaluat ions................................
.................................... 43
9.7.3 Applicat ion Site Ery thema Assessment .......................................................... 44
9.7.4 Physical Examinat ion.................................................................................... 44
9.7.5 Vital Signs..................................................................................................... 44
9.8 Other Assessments .................................................................................................... 44
9.8.1 Determinat ion of R -and S -Oxybutynin and N -desethylo xybut ynin Plasma 
Concentrations .............................................................................................. 44
9.8.2 Medical History ............................................................................................. 45
9.8.3 Electrocardiograms ........................................................................................ 45
9.8.4 Concomitant Medication Use ........................................................................ 45
9.8.5 Anticholinergic Symptoms Quest ionnaire ...................................................... 45
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 15of 749.8.6 Vision Symptom Questionnaire .................................................................... 45
9.9 Appropriateness of Measurements ............................................................................. 46
10QUALITY CONTROL  AND ASSURANCE ...................................................................... 47
11PLANNED ST ATISTICAL  METHODS ............................................................................. 48
11.1 Determinat ion of Sample Size ................................................................................... 48
11.2 Analysis Populat ions and Databases .......................................................................... 48
11.3 Efficacy Parameters .................................................................................................. 50
11.4 Descript ive Summaries of Efficacy Parameters ......................................................... 50
11.5 Statistical Analyses of Efficacy Parameters ............................................................... 51
11.5.1 Statistical Analysis o f the Primary Efficacy Endpo int.................................... 51
11.5.2 Statistical Analysis o f the Secondary  Efficacy Endpoints ............................... 51
11.5.3 Addit ional Analyses ...................................................................................... 51
11.5.4 Subgroup Analyses ........................................................................................ 52
11.6 Safety Analysis ......................................................................................................... 52
11.6.1 Adverse Events .............................................................................................. 52
11.6.2 Extent of Exposure ........................................................................................ 53
11.6.3 Laboratory  Evaluat ions and Abnormalit ies.................................................... 53
11.6.4 Vital Signs..................................................................................................... 54
11.6.5 Physical Examinat ions................................................................................... 54
11.6.6 Skin Assessments for Erythema ..................................................................... 54
11.7 Other Assessments .................................................................................................... 54
11.7.1 Dem ographic and Other Pretreatment Characterist ics.................................... 54
11.7.2 Medicat ions................................................................................................... 54
11.7.3 Com pliance ................................................................................................... 55
11.7.4 Urodynamic V ariables ................................................................................... 55
11.7.5 Anticholinergic Symptoms Questionnaire .................................................... 55
11.7.6 Vision Symptom Questionnaire .................................................................... 56
11.7.7 R-and S -Oxybut ynin and N -desethylo xybut ynin Plasma Concentrations ......56
12DATA HANDLING AND RECORDKEEPING .................................................................57
12.1 Data Generation and Analysis ................................................................................... 57
12.2 Access to Source Documentation .............................................................................. 57
12.3 Retention o f Data ...................................................................................................... 57
13OTH ER INFORMA TION .................................................................................................. 58
13.1 Financing and Insurance ............................................................................................ 58
13.2 Publicat ion and Disclosure Policy ............................................................................. 58
13.3 Terminat ion of the Study ........................................................................................... 58
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 16of 7414REFERENCE LIST ........................................................................................................... 59
15 APPENDICES ................................................................................................................... 60
Appendix 1 Schedule of Events .......................................................................... 61
Appendix 2 Clinical Laboratory  Evaluat ions...................................................... 62
Appendix 3 Sample 2 -Day Urinary  Diary ........................................................... 63
Appendix 4 Urodynamic Evaluat ion................................................................... 66
Appendix 5 Anticholinergic Quest ionnaire ......................................................... 67
Appendix 6 Vision Symptom  Questi onnaire for Parent/Caregiver ....................... 70
Appendix 7 Gel Applicat ion Instructions ............................................................ 71
Appendix 8 Vision Assessment Instructions for Site ........................................... 73
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 17of 744 LIST OF ABBREVIA TIONS AND DEFINITIONS OF TERMS
AE adverse event
ANCOV A analysis of covariance
CFB change from baseline
CFR Code of Federal Regulat ions
CIC clean intermittent catheterizat ion
DDA VP desmopressin
DEO N-desethylo xybut ynin
EC ethics commi ttee
ECG electrocardi ogram
eCRF electronic case report form
ET early  terminat ion
FDA Food and Drug Administration
GCP good clinical pract ice
HEENT head, ears, ey es, nose, throat
HIPAA Health Insurance Portabilit y and Accountabilit y Act
ICF informed consent form
ICH International Conference on Harmonisation o f Technical 
Requi rements for Registration of Pharmaceut icals for Hum an Use
ID identification
IND investigat ional new drug applicat ion
IRB institutional review board
ITT intent-to-treat
IVRS interact ive vo ice response system
LOCF last observat ion carri ed forward
MedDRA Medical Dict ionary for Regulatory  Activit ies
NF National Formulary
OC observed cases
PHI protected healt h informat ion
PK pharmacokinet ic
PP per protocol
SAE serious adverse event
TDS transderm al system
ULN upper limit of the normal range
USP United States Pharmacopeia
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 18of 745 ETHICS
5.1 Institutional Review Board or Ethics Committee
The protocol and supporting documents for this study  will be reviewed and approved by an 
appropriately  consti tuted inst itutional review board (IRB) or ethi cs co mmittee (EC) prior to 
study  initiation.
All reviews and approvals will be in accordance wit h GCP as contained in the ICH guidelines 
(E6) and US CFR governing IRBs (Tit le 21, Part 56).
A letter from the IRB or EC document ing approval of the invest igator (who must be ident ified by 
name), the protocol (must be identified by  title), and the pati ent consent form  must be received 
by the sponsor or its designee prior to study  initiation. A progress report will be submitted by  the 
investigator to the IRB or EC at intervals specified by the IRB or EC, but not less than annually . 
A copy  of this progress report will be sent to the sponsor . After com pletion of  the study , the 
investigator will submit a signed clinical safet y summary  of the study  to the IRB or EC.
5.2 Ethical Conduct of Study
The study  will be conducted in accordance with GCP as contained in ICH guidelines and US 
CFR governing the protection of human pat ients (Title 21, Part 50) and the obligat ions of clinical 
investigators (Tit le 21, Part 312.60 through 312.69). The study will also be conducted in 
accordance with the W orld Medical Associat ion Decl aration of Helsinki and all amendments.
The sponsor is responsible for the ongoing safet y evaluat ion of the study  treatm ent and will 
expedite the notificat ion of all part icipating investigators and regulatory authorit ies of findings 
that are both serious and unexpected and/o r that could adversely affect the safet y of patients or 
the conduct of the study , or al ter an IRB ’s or EC ’s approval to continue the study .
5.3 Patient Information and Consent
The invest igator will ensure that each patient will provide assent (if applicable an d according to 
IRB regul ations) and their parent(s) or legal guardian(s) will sign the written informed consent 
form in accordance with applicable regulations.
Patients and their parent(s) or legal guardian(s) will be interviewed at the init ial Screening Visit 
by qualified staff at the site and will be provided wit h a full descript ion of the nature and purpose 
of the study . The patients and their parent(s) or legal guardian(s) will be given adequate time to 
consider the risks associated with participation i n the study . Each pati ent will provide assent (if 
applicable and according to IRB regulat ions), and their parent(s) or legal guardian(s) will provide 
written inform ed consent pri or to parti cipat ing in any study  procedures. The original signed 
consent forms will be retained on file at the clinical sites and a copy  will be given to the patient. 
Case histori es (pati ent charts) will also document that informed consent was obtained prior to the 
patient’s parti cipati on in the study .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 19of 745.4 Authorization to Disclose Prot ected Health Information
If required under HIP AA regulat ions, patients and their parent(s) or legal guardian(s) will be 
inform ed of the fo llowing information:
The sponsor of the study
Any contractors that may  be invo lved in the study
The purpose of the pro tected health informat ion (PHI) being co llected
The possibilit y that the PHI m ay be re -disclosed
The durati on of  the authori zation
The patient ’s and parent ’s or l egal guardian ’s rights to revoke the authorizat ion; and
The ri ght of the pati ent and parent(s) or legal guardi an(s) to refuse signature and limit 
access to PHI during the conduct of the trial (US CFR Tit le 45, Parts 160 and 164)
Authori zation to di sclose PHI m ust be obtained before the patient enters the study .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 21of 747 INTRODUCTION
Oxybut ynin chloride is a well -known anticholinergic and ant ispasmodic agent that has gained 
widespread use in the pharmaco logical management of overact ive bladder over the past 
3decades. It has shown efficacy , safet y, and tol erabili ty in the treatm ent of both adult and 
pediatric patients . Oxybutynin is current ly available for use in adults as immediate -and 
extended -release oral  formulations, sy rup, transdermal delivery systems (TDS), and as 
oxybut ynin chloride gel (Gelnique®).
Oxybut ynin chloride gel  is formulated as a cl ear, colorless hydroalcoholic gel, available in a 
1gram unit dose that contains 100 mg oxybutynin chloride. This topical formulat ion was 
designed to provide the convenien ce of a once -a-day dosage form  with decreased ant icholinergic 
side ef fects com pared to oral  oxybut ynin products and improved skin tolerabilit y relative to the 
oxybut ynin TDS (Oxytrol®).
Phase 1 invest igations evaluat ing the pharmacokinetics and metabo lism of oxybutynin chloride 
geldemonstrated that the gel provided sustained systemic delivery  of therapeuti c levels of 
oxybut ynin.1 In a pharmacokinet ic (PK) study  in adul ts, applicati on of  1 g of  oxybutynin 
chloride gel produced comparable oxybut ynin absorpti on and plasma concentration profiles to 
3.9 m g/day  of Oxy trol transdermal  administrati on.1The applicat ion of oxybutynin chloride gel
to different anatomical sites (abdo men, thi ghs, and upper arm s/shoul ders) resulted in similar 
oxybut ynin absorption fro m all of the sites.2
A Phase 3 study  showed that oxybutynin chloride gel was effect ive in treating the symptoms of 
overactive bladder in adults and results from the same study  indicated that the gel was safe and 
well tolerated, with improved skin tolerabilit y over oxybut ynin transdermal systems.3
Neurogenic bladder is a condit ion characteri zed by overactivit y of both the detrusor and 
sphincter m uscles result ing in incont inence, urinary retent ion, and bladder infect ions. The vast 
majorit y of neurogenic bladder dy sfunct ion in the pediatric populat ion is the result of a 
myelo meningocele.4When not treated adequately this condit ion will eventually impa ct the heal th 
of the ki dneys.4Available data demonstrate that pediatric patients with detrusor overactivit y 
associ ated wi th a neuro logical condi tion may  benefi t from improved bladder control with 
anticholinergic treatment.5,6
This Phase 4 study  is being undertaken to provide informat ion on the safet y and efficacy of 
oxybutynin chloride gel in pediatric patients with neurogenic bladder dy sfunct ion. In a 
previously conducted Phase 4 clinical study , children wit h neurogenic bladder were treated with 
oxybut ynin TDS.7This study  dem onstrated that treatm ent wi th either 2.6 m g/day or 3.9 m g/day  
oxybut ynin TDS improved the symptoms of detrusor overactivit y and the urodynamic 
paratm ers.7Oxybut ynin and N -desethylo xybutynin (DEO) metabo lite plasma concentrations in 
these pediatric patients did not differ significantly fro m those observed in adults administered 
Oxytro l (3.9 m g/day ), suggest ing co mparable oxybutynin chloride bioavailabilit y and 
metabo lism in adult s and c hildren.7Therefore, the proposed doses of 0.5 g, 0.75 g, and 1 g 
oxybutynin chloride gel are in the range of oxybutynin TDS doses previously evaluated and 
shown t o be safe and effect ive in this pediatric populat ion.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 22of 74The current standard of treatment is a combinat ion of clean intermittent catheterizat ion (CIC) 
and an anticholinergic agent, such as oxybut ynin.6This combinat ion has shown statist ically 
significant and clinically meaningful changes from baseline in catheterization urine volume, as 
well as improvements in the percentage of catheterizat ions wit hout l eakage and in key  
urodynamic parameters.8These same clinical and urodynamic parameters will be used in the 
present study  to eval uate the safet y and efficacy of oxybutynin chloride gel when administered 
to pediatr ic patients .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 23of 748 STUDY OBJECTIVES
8.1 Primary Objectives
The primary  object ives of this study are:
Pre-amendment 3 : To eval uate the efficacy  ofdaily  treatm ent with oxybutynin chloride gel 
compared to placebo in pediatric patients during the first 6 weeks of a 14 -week treatment 
period.
Post- amendment 3: T o evaluate the efficacy of daily treatment with oxybutynin chloride gel 
in pediatric patients during the first 6 -weeks of a 14 -week open -label treatment period.
8.2 Secondary Objectives
The secondary  objectives of thi s study  are to evaluate the pharmacokinet ics, pharmacodynamics, 
safet y, and skin tolerability of oxybutynin chloride gel in pediatric patients .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 24of 749 INVESTIGA TIONAL PLAN
9.1 Overall Study Design and Plan
This study was initiated as a double- blind, placebo -controlle d study  with an open -label 
extension, and is now amended to continuing to enroll patients under only open -label 
treatment.
Pre-Amendment 3, patients ages 6 to >17 years, were randomly assigned 1:1 to receive double-
blind oxybutynin chloride gel or placebo gel for 6 weeks, followed by an open -label, 8- week 
period to generate safety data. All patients began treatment with 0.75 g of gel/day for 2 weeks. 
Patients then returned to the clinic for a potential dose titration and at this time their dose 
could have b een adjusted up to 1 g/day , down to 0.5 g/day , or remained the same at 0.75 g/day . 
The determination of dose was based on the investigator’ s clinical judgment and assessment of 
the patient ’s bladder symptoms and treatment side effects.
Dose titration was p ermitted only once during the entire 6- week double -blind, placebo -
controlled period. Patients continued blinded treatment for 4 additional weeks until the end of 
the double -blind treatment period. Pre -Amendment 3, visits were identified numerically 
(ie,Visit 1 through V isit 8/Early T ermination).
Post-Amendment 3, this study will continue as an open- label study for new patients enrolled 
under the present protocol (Amendment 3), with a similar patient population (ie, pediatric 
patients who have been diagnos ed with detrusor overactivity that is associated with a 
neurogenic condition) and will also enroll younger patients (minimum age of 3 years).
For patients enrolled under Post -Amendment 3, this will be a multicenter , open -label, dose -
titration study in pedi atric patients, ages 3 years to <17 years , who have been diagnosed with 
detrusor overactivit y that i s associ ated wi th a neurogeni c condi tion. Patients must be suitable 
candidates for anticho linergic therapy and must be using CIC for bladder control. No ch anges 
were made in the starting dose, compared to the Pre -Amendment 3 study design, in that all 
patients will begin treatment with 0.75 g of gel/day for 2 weeks. Patients will then return to the 
clinic for a potential dose titration and at this time their dose may be adjusted up to 1 g/day , 
down to 0.5 g/day , or remain the same at 0.75 g/day , depending on individual response and 
tolerability . The determination of dose will be based on the investigator ’s clinical judgment 
and assessment of the patient ’s blad der symptoms and treatment side effects. Dose titration 
will be permitted only once during the entire 14 -week treatment period. Patients will continue 
the adjusted dose for 12 additional weeks until the end of the open -label treatment period. 
Post- Amendmen t 3, visits will be identified alphabetically (ie, V isit A  through V isit F/ET) .
In the Post -Amendment 3 study design (open -label treatment only), the study will consist of a 
screening period from Day -13 to Day -5 and a 14 week open -label treatment period. The total 
study duration for each patient will be approximately 16 weeks.
The screening period will include 1clinic visit; Visit A(Screening V isit), where patients will be 
considered for inclusio n in the study . Following V isit A, all patients taking ant icholinergic 
medicat ions will be asked to discont inue treatment and complete a 3 -day washout period ( 11-day 
washout period if the patient was previously taking solifenacin ). In addit ion, patients will be 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 27of 749.3.2 Exclusion Criteria
Patient will be excluded from part icipation if they meet any o f the following criteria:
EX01. Are pregnant or lactating
EX02. Have a pat ient-reported average CIC of more than 6 times per 24 -hour period during the 
screening period, as captured by  the 2 -day urinary  diary
EX03. Have 1 or m ore treatabl e condi tions, other than neurogenic bladder dy sfunct ion, that may 
cause urinary  incont inence or urgency (eg, urinary tract infect ion or requirement for acute 
to intermittent use of diuret ics)
Note: Patients with evidence of acu te urinary  tract infect ion may receive treatment and 
then be re -evaluated for entry  into the study . Asymptomat ic bacteriuria, which can be
associ ated wi th CIC, i s notan exclusio nary condi tion.
EX04. Have any medical condit ion that precludes their safe par ticipat ion in the study  or m ay 
confound the outcome of the study  (eg, hi story  of lower urinary  tract surgery  within 6 
months of screening, > 2 urinary tract infections wit hin 6 mo nths of screening, unstable 
diabetes m ellitus; hydronephrosi s unrel ated to ne urogeni c bladder, or reflux Grade 4 or 5)
EX05. Have ECG with clinically significant abnormal results
EX06. Have had surgical bladder augmentation (eg, use of ileum or colon to provide surgical 
expansio n of bladder capacit y, gastrocystopl asty, detrusor my otomy) wi thin 1 year of 
screening
EX07. Have any anatomical abnormalit ies of the urinary tract sy stem  that can affect bladder 
funct ion
EX08. Have an act ive skin disorder, such as eczema, seborrhea, or psoriasis affect ing the gel 
applicat ion areas
EX09. Have a known hypersensit ivity or other contraindication to anticho linergic medicat ions 
EX10. Requi re treatm ent wi th medicat ions that may interfere with the metabo lism o f 
oxybut ynin, including ant imycotic agents (eg, ketoconazole, itraconazo le, miconazo le), 
macrolide antibiot ics (eg, erythro mycin, clarit hromycin), other anticho linergic agents 
(eg, oxybut ynin, propantheline, dicyclomine, flavoxate, hyoscyamine , tolterodine, 
darifenacin), or desmopressin (DDA VP)or requi re concomi tant m edicat ions that m ay 
affect detrusor activit y, including tricyclic ant idepressants (eg, imipramine, doxepin, 
desipramine, nortript yline, trimipramine, clo mipramine, protript yline)
Note: Patients who are taking excluded medicat ions prior to starting the study  can 
participate in the st udy only if the excluded medications can be safet y discont inued at 
least 3 day s before the init iation of the urinary  diary . Patients who are taking so lifenacin 
(Vesicare®) shoul d discont inue treatment at least 11 days prior to the init iation of the 
urinary diary .
EX11.Have part icipated in another invest igational drug study within 30 days prior to the 
Baseline Visit
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 28of 74EX12. Have been diagnosed with asymmetric/unequal or severe refractive error in either eye 
prior to the Baseline V isit. If a patient < 8 years old has known risk factors for eye 
disease before starting treatment (ie, family history of pediatric eye disease and/or 
symptoms of a vision disorder) it will be recommended, at the discretion of the 
investigator , that a comprehensive eye examination is p erformed by a pediatric 
ophthalmologist prior to enrollment.
9.3.3 Patient Identification
Patient study  identificat ion numbers will be assigned at the Screening V isit. Patient numbers will 
be consecutive at each study  site beginning wi th 001. Pati ent numbers wil l consist of the si te 
number (3 digits) fo llowed by  the pat ient number (3 digit s) at that site. Patient identificat ion 
numbers will be used throughout the trial.
9.3.4 Rem oval of Patients from Treatment or Assessment
An attem pt will  be made to i dentify and fo llow every  patient enrolled in the study  through to 
completion. If a patient withdraws, or is withdrawn fro m the study  by the invest igator , the reason 
and circumstances for such early terminat ion must be fully documented.
Patients may be withdrawn fro m treatm ent for the occurrence of a serious adverse event ( SAE ) 
or any  other condi tion that m ay create a safet y risk. The sponsor must be informed wit hin 48 
hours if any  patient withdraws fro m the study  regardl ess of cause. Patients who are withdrawn 
from the study  may not be re -enrolled.
9.4 Study Treatments
9.4.1 Treatments Administered
Pre-Amendment 3, patients were randomized to receive oxybutynin chloride gel or placebo 
during the 6 -week double -blind treatment period, and all patients received oxybutynin chloride 
gel during the 8 -week open -label treatment period. Patients randomized to double- blind 
oxybutynin chloride gel started treatment at 0.75 g/day , and the dose may have been adjusted 
after 2 weeks of treatment to a higher or lowe r dose (0.5 g/day or 1 g/day) based on the 
investigator ’s clinical judgment and assessment of bladder symptoms and treatment side 
effects. All patients who entered the open -label safety period were started on 0.75 g/day 
oxybutynin chloride gel, and the dos e may have been adjusted after 2 weeks of treatment as 
described for the double -blind treatment period.
Post-Amendment 3, no changes were made in the starting dose, compared to the 
Pre-Amendment 3 study design, in that all patients will begin treatment wit h 0.75 g of gel/day 
for 2 weeks. Patients will then return to the clinic for a potential dose titration and at this time 
their dose may be adjusted up to 1 g/day , down to 0.5 g/day , or remain the same at 0.75 g/day , 
depending on individual response and tol erability . The determination of dose will be based on 
the investigator ’s clinical judgment and assessment of the patient’s bladder symptoms and 
treatment side effects. Dose titration will be permitted only once during the entire 14 -week 
treatment period. P atients will continue the adjusted dose for 12 additional weeks until the end 
of the open -label treatment period.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 29of 74Patients or parents/ caregiver will apply  the gel each m orning to rotating applicat ion sites on the 
abdo men, upper arms/shoulders, and thighs. The person who applies the gel should wash his or 
herhands immediately after applicat ion with soap and water .
Patients should not bathe or shower sooner than 1 hour fo llowing a gel  applicati on. In the event 
of direct contact between unwashed or unclothed skin to which gel has been applied and the skin 
of another person, the con tact area on the other person should be washed wit h soap and water as 
soon as possible.
9.4.2 Identity of Study Treatment
9.4.2.1 Description of Study Treatment
Oxybutynin chloride gel is a pH 6.0 clear, colorless, hydroalcoho lic gel containing 100 mg of 
oxybut ynin hydrochloride salt per gram of gel. Each gram is designed to deliver approximately 
4mg oxybut ynin to the sy stemic circulat ion. Inact ive ingredients are alcoho l, USP; glycerin, 
USP; hydr oxypropyl cellulose, NF; sodium hydroxide, NF; and purified water, USP . The 0.5 g, 
0.75 g, and 1 g doses are of ident ical co mposit ion and differ only in the amount of gel applied.
The study treatment is manufactured in accordance with current Good Manufact uring Practice 
and will be distributed to study centers by the sponsor .
9.4.2.2 Packaging, Labeling, and Dispensing
The study treatment will be packaged in individual patient cartons containing a sufficient supply 
of sachets for the completion of thetreatm ent per iod, plus an addit ional amount for supplies that 
are mishandled. Each patient carton will be co lor-coded by  dose level (0.5, 0.75, or 1 g) . The 
gel will be supplied as individually pouched 0.5 g, 0.75 g, and 1 g dose sachets of the active gel. 
Each sachet will be labeled with the protocol number , study treatment identification (ID), 
contents, caution statement ( Caution: New Drug –Limited by Federal Law to Investigational 
Use) and thesponsor ’s name and address. These labeled sachets will be packaged in vis it cartons 
to be dispensed to patients at their clinic visit s. Two-part labels will be attached to each visit 
carton: one part will remain on the container and one will be detached when the container is 
dispensed to the study  patient. The carton will be la beled with the protocol number , medication 
ID, contents, caution statement, the sponsor ’s name and address, and directions to apply 
contents of 1 sachet daily as directed. Immediately before dispensing the study treatment, the 
Investigator will write the patient ’s 6 -digit identification number , patient ’s initials, and date 
dispensed on the label. The detachable portion will contain the dosing information for each 
patient (ie, the starting dose of 0.75 g/day , or a later modified dose level of 0.5 or 1 g/day ). 
Dosing information will be recorded on the electronic case report form ( eCRF ).
9.4.2.3 Storage and Accountability
The study treatment will be stored in a secure location at controlled room temperature, 20°C to 
25°C/68° to 77°F (with excursio ns allowed between 15 °C and30°C/ 59°F and 86°F ) and away  
from direct sunlight.
The invest igator shall maintain accurate study treatment inventory records, including the 
quant ities and date of receipt of supplies fro m the sponsor, and the quantit ies and dates of 
dispensing to s tudy parti cipants. All study treatment supplies must be accounted for at study  
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 30of 74termination and a written explanat ion provi ded for any discrepancies. All unused supplies shall 
be returned to the sponsor or, if authorized in writ ing by the sponsor, destroyed properly at the 
study  site. Shipping and handling of all study treatment will conform to FDA  regul ations for 
investigat ional drug products.
Reasons for departure from the expected dispensing regimen will also be recorded. At 
completion of the study , to sati sfy regulatory  requirem ents regarding drug accountabilit y, all 
study treatment supplies will be stored, inventoried, reconciled, and destroy ed or returned to the 
sponsor according to applicable state and federal regulat ions. A  written explanat ion must be 
provi ded for any  discrepancies. The study  monitor must review all records of invest igational 
supplies prior to the return or destruction of any study treatment .
9.4.3 Method of Assigning Patients to Treatment Groups
Pre-Amendmen t 3, patients were randomized to oxybutynin chloride gel or placebo treatment in 
a 1:1 rati o within each stratificat ion level, using an interactive vo ice recognit ion system (IVRS). 
Enrollment was stratified based on sex, age, and weight. Stratificat ion wasdone wi thin the 
following groups: male and female; 6 to < 12 years -of-age and 12 to < 17 y ears-of-age; and 
≤25.0 kg and > 25.0 kg for the 6 to < 12 years -of-age group and ≤ 50.0 kg and > 50.0 kg for the 
12 to < 17 years -of age group.
Post- Amendment 3, no changes were made in the starting dose, compared to the Pre -
Amendment 3 study design, in that all patients will begin treatment with 0.75 g of gel/day for 
2 weeks. Patients will then return to the clinic for a potential dose titration and at this time 
their dose may be adjusted up to 1 g/day , down to 0.5 g/day , or remain the same at 0.75 g/day , 
depending on individual response and tolerability . All patients will be assigned to oxybutynin 
chloride gel; patient enrollment will not be stratified.
9.4.4 Selection of Doses and Timing of Administration in the Study
Pre-Amendment 3, patients were randomized to receive oxybutynin chloride gel or placebo 
during the 6 -week double -blind treatment period, and all patients received oxybutynin chloride 
gel during the 8 -week open -label treatment period. Patients randomized to double- blind 
oxybutynin chloride gel started treatment at 0.75 g/day , and the dose may have been adjusted 
after 2 weeks of treatment to a higher or lower dose (0.5 g/day or 1 g/day) based on the 
investigator’s clinical judgment and assessment of bladder symptoms and treatment side 
effects. All patients who entered the open -label safety period were started on 0.75 g/day 
oxybutynin chloride gel, and the dose may have been adjusted after 2 weeks of treatment as
described for the double -blind treatment period.
Post-Amendment 3, no changes were made in the starting dose, compared to the 
Pre-Amendment 3 study design, in that all patients will begin treatment with 0.75 g of gel/day 
for 2 weeks. Patients will then return to the clinic for a potential dose titration and at this time 
their dose may be adjusted up to 1 g/day , down to 0.5 g/day , or remain the same at 0.75 g/day , 
depending on individual response and tolerability. The determination of dose will be based on 
the investigator ’s clinical judgment and assessment of the patient’s bladder symptoms and 
treatment side effects. Dose titration will be permitted only once during the entire 14 -week 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 32of 749.4.7 Treatment Compliance
Com pliance wi th the assigned study  treatm ent regimen will be assessed by co mpar ing the 
number of sachets expected to be used as based on th e total  number of treatm ent days wi th the 
actual number used (expressed as percentage of use/expected). Compliance will be assessed and 
recorded at each clinic visit and for the overall study .
9.5 Study Activities
The fo llowing sect ions (Sections 9.5.1 to 9.5.4) provide details of the study  activit ies 
Post
-Amendment 3 (ie, only open -label enrollment). Note that alterations from prior details 
are shown in bold italics and are further enumerated in th e accompanying Summary of 
Changes document. A schedule of events table is presented in Section 15, Appendix 1.
9.5.1 Screening Period ( 5 to 13 Days )
The screening period will occur from Day -13 to Day -5and will include 1 clinic visit, V isit A
(Screening V isit), where patients will be considered for inclusio n in the study . Foll owing V isit A, 
all patients taking ant icholinergic medications will be asked to complete a 3 -day minimum 
washout period ( 11-day washout period if the patient was previously taking solifenacin). 
Following the washout period, patients (or parents/caregivers) will co mplete a 2 -day urinary  
diary on 2consecut ive days, prior to V isit B . To minimize off -treatm ent time, patients may 
complete the washout period and urinary  diary  as cl ose to V is
it Bas possible. All evaluat ions and 
procedures that will be conducted during the sc reening period are listed below in Sect ion 9.5.1.1 .
9.5.1.1 Visit A(Screening Visit)
Site personnel will perform the fo llowing:
1.Provi de detailed explanat ion of the study .
2.Obtain informed consent and assent (if applicable)
3.Vision screening assessment. Prior to Baseline Visit patients who are < 8 years of age 
at the time of screening who have not had a vision examination in the last 12 months 
prior to screening a re required to have a vision assessment prior to or at the baseline 
visit. The vision assessment can be performed at the study site or a separate site by a 
healthcare professional [nurse, technician, or physician] with the appropriate 
training.
4.Assign 6 –digi t identificat ion number using IVRS
The fo llowing evaluations must be completed before V isit B(Baseline Visit):
5.Review and document pertinent inclusio n and exclusion criteria.
6.Record demographic information (sex, race, ethnicit y, and date of b irth).
7.Obtain medical history , including a history  of the pati ent’s incontinence.
8.Obtain prior and current m edicati on use informat ion.
9.Measure and record height and weight.
10.Measure and record vital signs (bl ood pressure, heart rate, respirator y rate, and 
temperature).
11.Record output of 12 -lead electrocardiogram.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 33of 7412.Conduct phy sical examinat ion, which will include a review of the following: body as a 
whole; skin; head, ears, eyes, nose, throat (HEENT); cardiovascular; respiratory; 
musculoskeletal; neurologic; lymphatic/thy roid; and abdo men.
13.Collect blood and urine samples for laboratory  evaluat ion, including urinalysis and urine 
culture (Appendix 2).
14.Collect urine sample for pregnancy test for all females of childbearing potential 
(Appendix 2).
15.Instruct patients to complete a 3 -day minimum washout period, if patients are present ly 
on anticho linergic or other excluded medicat ion (11-day washout period if the patient 
was previously taking solifenacin ).
16.Dispense 2
-day urinary  diary  and review instructi ons for i ts com pletion (Appendix 3). 
Remind patients/caregivers that the urinary  diary  must be com pleted foll owing the 
washout period, but prior to scheduled Visit B. The pati ent/caregiver shoul d not be 
inform ed of the minimum diary requirements for eligibilit y.
17.Patients < 8 years old who have not had a vision examination in the last 12 months 
prior to screening will require a vision screening assessment prior to or at the 
Baseline Visi t (Appendix 8). The vision assessment can be performed at the study site 
or a separate site by a healthcare professional (nurse, technician, or physician) with 
the appropriate training.
9.5.2 Open -label Treatment Period (14 Weeks)
The 14-week, open -label treatm ent peri od will  begin atVisit B(Baseline Visit, W eek 0 of  
treatm ent). Patients should have completed the washout period and the 2 -day urinary diary prior 
to Visit B. If patie ntscontinue to meet eligibilit y criteria at V is
it B, a urodynamic evaluat ion will 
be conducted. All patients will apply  0.75 g of gel  daily  to rotating si tes located on the abdo men, 
upper arms/shoulders, or thighs. If patients are not able to apply the studytreatment, thei r 
caregivers should perform this task on a daily basis.
9.5.2.1 Visit B(Baseline Visit) (Week 0 of Treatment)
Site personnel will perform the fo llowing act ivities atVisit B:
1.Collect and review 2 -day urinary  diary  and data.
Patients who accurately co mplete the 2 -day urinary  diary but do not m eet entry  criteria 
based on number of catheterizations will not undergo further evaluat ion procedures. 
Patients who fail to accurately co mplete the urinary diary may be allowed to repeat the 
diary eval uation at the di screti on of  the invest igator. Patients who then meet the criteria 
will be allowed to complete Visit Bevaluat ion procedures. Patients failing to qualify for 
the study  after the second di ary attem pt will  be withdrawn from  further study  
participat ion.
2.Update m edical history  and current m edicat ion use.
3.Review and document pertinent inclusio n and exclusion criteria.
4.Measure vital s igns (blood pressure, heart rate, respiratory  rate and tem perature).
5.Collect urine sample for urinalysis (use on site dipstick to determine presence of 
infect ion).
6.Perform  urodynamic evaluat ions (Appendix 4).
7.Instruct patient/caregiver to complete the anticho linergic quest ionnaire ( Appendix 5) 
andvision symptom questionnaire (Appendix 6).
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 34of 748.Dispense study treatment kit (dose of 0.75 g/day ), if the inclusio n/exclusion criteria are 
met.
9.Instruct patient/caregiver on study treatment application ( Appendix 7) and supervise 
applicat ion of first dose.
10.Patients < 8 years old who have not had a vision examination in the last 12 months 
prior to screening will be required to have a vision screening test prior to or at the 
Baseline V isit (Appendix 8). The vision assessment can be performed at the study site 
or a separate site by a healthcare professional (nurse, technician, or physician) with 
the appropriate training.
9.5.2.2 Visit C(Week 2 of Treatment) Dose Titration Opportunity
Patients will return to the clinic after 2 weeks of treatment for evaluat ion and a dose titration 
opportunit y. Site personnel will perform the fo llowing act ivities:
1.Perform study treatment accountabilit y
.
2.Record concomitant medicat ion use.
3.Measure andrecord vital signs (bl ood pressure, heart rate, respiratory  rate, and 
temperature).
4.Query  for adverse events.
5.Assess ery thema/applicat ion site adverse events at most recent application site and
docum ent findings.
6.Dose ti tration: Based on the invest
igator’s clinical judgment and assessment of bladder 
symptoms and treatment side effects, the dose can remain the same at 0.75 g/day , be 
increased to 1 g/ day, or canbereduced to 0.5 g/day .
7.Collect bl ood sam ple for PKanalysis and record the date and time of co llection. Record 
date and time of last 2 days gel applicat ions (visit date and day prior ).
8.Dispense study treatment kit for thenext 4 weeks of treatment and instruct 
patient/caregiver on study treatment application ( Appendix 7).
9.Dispense 2 -
day urinary diary and remind patients that the urinary diary must be 
completed in the week prior to Visit D.
10.Instruct patient/caregiver to complete the anticholinergic questio nnaire ( Appendix 5) 
and the vision symptom questionnaire ( Appendix 6).
9.5.2.3 Visit D(Week 6 of T
reatment)
Site personnel will perform the fo llowing act ivities atVisit D:
1.Perform study treatment accountability.
2.Collect and review 2-day urinary diary and data.
3.Record concomitant medication use.
4.Measure and record vital signs (blood pressur e, heart rate, respiratory rate, and 
temperature).
5.Query for adverse events.
6.Assess erythema/application site adverse events at the most recent application site and 
document findings.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 35of 747.Instruct patient/caregiver to complete the anticholinergic ques tionnaire ( Appendix 5) 
and vision symptom questionnaire ( Appendix 6).
8.Perform urodynamic evaluations ( Appendix 4).
9.Dispense study treatment kit for the next 4 weeks of treatme nt.
10.Collect urine sample for pregnancy test for all females of childbearing potential 
(Appendix 2).
11.Collect blood sample for PK analysis and record the date and time of collection.
12.Record date and time of last 2 days of gel applications (visit date and day prior).
9.5.2.4 Visit E(Week 10 of Treatment)
Site personnel will perform the fo llowing act ivities at V isit E:
1.
Perform study treatment accountability.
2.Record concomitant medication use.
3. Measure and record vital signs (blood pressure, heart rate, respiratory rate, and 
temperature).
4.Query for adverse events.
5. Assess erythema/application site adverse events at the most recent application site and 
document findings.
6. Instruct patient/caregiver to complete the anticholinergic questionnaire ( Appendix 5) 
and vision symptom questionnaire ( Appendix 6).
7.Dispense study treatment kit for the next 4 weeks of treatment.
9.5.2.5 Visit F (Week 14 of Treatment) or Early Termination
Visit F will be the end of the open -label treatment period. Patients will undergo e valuat ion 
by 
site personnel who will perform the following act ivities:
1.Collect rem aining study  treatm ent and perform study  treatm ent accountabilit y.
2.Record concomitant medicat ion use.
3.Measure and record vital signs (bl ood pressure, heart rate, res piratory  rate, and 
temperature).
4.Query  for adverse events.
5.Assess ery thema/applicat ion site adverse events at the most recent applicat ion site and 
document findings .
6.Instruct patient/caregiver to complete the anticho linergic quest ionnaire (Appendix 5) 
and the vision symptom questionnaire ( Appendix 6).
7.
Conduct physical examination, which will include a review of the following: body as a 
whole, skin, HEENT, cardiovascular, respiratory; musculoskeletal, neurologic, 
lymphatic/thyroid, and abdom en.
8. Collect blood and urine samples for laboratory evaluation ( Appendix 2).
9.Collect urine sample for pregnancy test for all females of childbearing potential 
(Appendix 2).
10.
Collect blood sample for PK analysis and record the date and time of collection.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 36of 749.5.3 Exit/Early Termination Visit
Study  site personnel  will make every attem pt to fo llow the progress of every pat ient admitted to 
the study  through to study  com pletion. If a patient fails to return for a scheduled visit, a 
reasonable effort should be made to contact the patient and ascertain the reason(s) for not 
returning.
If a patient does not complete the study  for any  reason (including invest igator discret ion), the 
reason and circumstances for the patient ’s early terminat ion must be fully documented. If 
possible, the assessments specified for the exit visit should be per formed.
The sponsor must be informed within 48 hours if any  patient wi thdraws fro m the study , 
regardl ess of the cause. Withdrawn patients m ay not be re -enrolled in the study  and will not be 
replaced.
9.5.4 Early Termination Activities
Upon pati ent wi thdrawal/ear ly discontinuat ion from the study , all evaluat ions scheduled at 
VisitF(Week 14of treatm ent) shoul d be com pleted at the terminat ion visit. If the early 
termination visit occurs immediately after a visit in which a diary had been previously dispensed, 
thediary  will be reviewed and collected.
9.6 Efficacy Assessment
The efficacy endpo ints of the study  will be eval uated based on informat ion derived fro m the 
2-day urinary  diaries and urodynamic assessments recorded at baseline and during the treatment 
period.
9.6.1 Urinary Diary
The urinary  diaries will  be com pleted by  each patient/caregiver during the week before Visit B 
and V isit D . The 2 -day urinary  diary  will be used to collect informat ion for the param eters listed 
below . A sample urinary  diary  is provided in Appendix 3.
Number of catheterizat ions per day
Volume of urine collected at each ( after morning awakening) catheterization
Leakage incidents between catheterizat ions
9.6.2 Efficac y Variables
9.6.2.1 Primary Efficacy Variable
The primary  efficacy endpoint is the change from baseline (CFB) to W eek 6 of treatment or the 
last observation carried forward (LOCF) in the percentage of catheterizations without a leaking 
accident as recorded in the 2- day urinary diary .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 37of 749.6.2.2 Secondary Efficacy Variables
Secondary endpoints include the CFB to W eek 6 of treatment in the following (calculated from 
the 2-day urinary diary data):
Average vo lume of urine co llected per catheterization ( for Pre -Amendment 3 populat ion 
only);
Average vo lume of urine co llected at first (morning awakening) catheterization;
Average number of catheterizat ions per day
9.6.2.3 Urodynamic Variables
Pharmacodynamics will be assessed for treatment under the Pre- Amendment 3 double -blind 
phase, treatment under the Post -Amendment 3 open -label phase, and both groups aggregated 
where appropriate. Pharmacodynamics will be based on urodynamic testing. The fo llowing 
parameters will be evaluated :
Maxim albladder capacit y
Detrusor pressures at maximum ca pacity
Maximum amplitude of invo luntary detrusor contractions
Volume at first involuntary  detrusor contracti on
Presence (versus total absence) of invo luntary detrusor contracti ons at > 15 cm H2O
9.7 Safety Variables
Analyses and summaries will be performed for treatment under the Pre -Amendment 3 double -
blind phase, the Pre- Amendment 3 open -label phase, and the Post -Amendment 3 open- label 
phase, with groups aggregated where appropriate.
Patients must be evaluated by a physician or an appropriately trained healt hcare professional 
at every visit, and the evaluation must be documented. The procedures discussed below will be 
completed at the designated visits. Safety assessments should not be administered to the patient 
unless the patient is accompanied by his or he r consented caregiver .
Safety evaluations will include the following:
Adverse events
Physical examinat ion
Vital signs (blood pressure, heart rate, respiratory  rate, and tem perature)
Clinical laboratory  evaluat ions including hematology , serum  chemistries, a nd urinalysis
Erythema at the gel  applicat ion site
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 38of 74Vision assessment in children < 8 years old prior to or at the Baseline V isit
Visual assessment by investigator or designee ( Appendix 8) and by using a visual 
symptom questionnaire ( Appendix 6).
9.7.1 Adverse Events
An AE is any untoward medical occurrence in a patient or clinical investigation patient
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding, for example), symptom, or di sease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product (ICH -E2A).
For the purpose of the site ’s data collection responsibilities, any untoward event that was 
reported from the patient sig
ned the informed consent form (ICF) until 30 days after the final 
protocol -defined study visit or , if the final visit does not occur , the last known dose of study 
treatment is to be considered an AE.
Examples of AEs are as follows:
Changes in the general c ondition of the patient
Subjective symptoms offered by or elicited from the patient
Objective signs observed by the investigator or other study site personnel
All diseases that occur after signing informed consent, including any change in 
severity or frequency of pre -existing disease
All clinically relevant abnormalities in laboratory values or clinically relevant physical 
findings that occur during the study schedule
Please note that medical procedures scheduled prior to consenting, but occurring duri ng the 
study should not be captured as AEs, but should be listed in the medical history if related to a 
pre-existing condition.
9.7.1.1 Causality Assessment
For each AE, the investigator must provide an assessment of causal relationship to the study 
treatment. The causality assessment must be recorded on the eCRF . Causal relationship must 
be assessed by answering the following question:
Is there a reasonable possibility the study treatment caused the event?
Yes: There is evidence to suggest a causal relationship be tween the study treatment and AE, ie:
There is a reasonable temporal relationship between the study treatment and the event, 
and/or
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 39of 74The event is unlikely to be attributed to underlying/concurrent disease, other study 
treatments, or other factors, and/or
Positive dechallenge and/or rechallenge exist
No: There is no evidence to suggest a causal relationship between the study treatment and AE, 
ie:
There is no reasonable temporal relationship between the study treatment and the 
event, or
The patient did not ta ke the study treatment, or
The event is likely to be attributed to underlying/concurrent disease, other study 
treatments, or other factors, or
The event is commonly occurring in the (study) population independent of study 
treatment exposure
9.7.1.2 Severity Asses sment
The investigator will provide an assessment of the severity of each AE by recording a severity 
rating on the appropriate page of the patient ’s eCRF . Severity , which is a description of the 
intensity of manifestation of the AE, is distinct from seriousness, which implies a patient 
outcome or AE -required treatment measure associated with a threat to life or functionality . 
Severity will be assessed according to the following scale:
Mild: A type of AE that is usually transient and may require only m inimal treatment 
or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.
Moderate: A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention.
9.7.1.3 Serious Adverse Event
An SAE is any untoward medical occurrence that at any dose:
Results in death
Is life threatening
Requires inpatient hospitalization or prolongation of existing hospitalization
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 40of 74Results in persistent or significant disability/incapacity , or
Is a congenital anomaly/birth defect
Important medical events that may not result in death, be life threatening, or require 
hospitalization may be considered serious when, based on appropriate medical judgment, th ey 
may jeopardize the patient and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in patient hospitalization, or the development of 
study treatment dependency or drug abuse.
Emergency room visits that do not result in hospitalization should be evaluated for one of the 
other seriou s outcomes to determine whether they qualify as SAEs.
Preplanned hospitalizations (eg, elective procedures for pre -existing conditions that did not
worsen, such as cosmetic surgery and hysterectomy) are excluded from SAE reporting.
9.7.1.4 Reporting Adverse Events and Serious Adverse Events
At each visit, patients are to be queried regarding any AEs or SAEs that have occurred since 
the previous visit. Patients will be asked to volunteer information with a nonleading question 
such as, “How do you feel since your las t visit? ” Study site personnel will record all pertinent 
information in the patient ’s eCRF .
All AEs must be recorded on the appropriate AE reporting page of the patient ’s eCRF whether 
or not they are considered causally related to the study treatment.
For every AE, the investigator must:
Provide an assessment of the seriousness of the event (ie, is it an SAE?), as well as the 
severity and causal relationship
Document all actions taken with regard to the study treatment
Detail any other treatment measures ta ken for the AE
Document the outcome of the AE
In addition, patients are to be reminded, as described in the ICF and in accordance with 
Section 9.7.1 , to notify site personnel of any AEs occurring during the 30 day post -study 
period. Any AEs reported by the patient (or patient representative) during this period are to be 
recorded in original source documents. AEs are also to be recorded in the eCRF if at least one
of the following conditions is met: 1) the event meets the criteria for an SAE (see 
Sections 9.7.1.3 and 9.7.1.5 ), and/or 2) the event is judged by the Investigator to be potentially 
causally related to study treatment.
Any AEs that are ongoing at the time of the final protocol -defined study visit will be followed 
until the condition returns to prestudy status, has resolved or stabilized, or can be explained as 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 41of 74being unrelated to the study treatment. If a follow -up visit is deemed necessary for appropriate 
safety surveillance, it will take place within 30 days of the final pr otocol -defined study visit.
9.7.1.5 Immediate Reporting of Serious Adverse Events and Events of Special Interest
The Sponsor is required to inform worldwide regulatory authorities of SAEs that meet specific 
criteria. Therefore, the Sponsor must be notified immediately regarding any SAE that occurs 
after informed consent is obtained.
Within 24 hours of learning of any AE that meets one of the criteria for an SAE, the study site 
personnel must report the event to AbbV ieGlobal Drug Safety on the SAE Form for C linical 
Trials. The Sponsor ’s Study Physician may also be notified by telephone.
If, during follow -up, any nonserious AE worsens and eventually meets the criteria for an SAE, 
that AE should be recorded as a new SAE.
The site must transmit the SAE Form for Clinical Trials to the SAE fax number shown below . 
Even if an initial report is made by telephone, the SAE Form for Clinical Trials completed 
with all available details must still be faxed within 24 hours of knowledge of the event at the 
study site.
Supple mental information should be submitted as soon as available and may include 
laboratory results, radiology reports, progress notes, hospital admission and emergency room 
notes, holding and observation notes, discharge summaries, autopsy reports, and death 
certificates.
The investigator is expected to take all therapeutic measures necessary for resolution of the 
SAE. Any medications or procedures necessary for treatment of the SAE must be recorded on 
the appropriate pages of the patient ’s eCRF . All SAEs are t o be followed by the study staff 
until resolution or until the SAE is deemed stable. The Sponsor may contact the study site to 
solicit additional information or follow up on the event.
Fax the SAE Form for Clinical Trials to AbbV ieInc.
Global fax number for SAE or Pregnancy Reporting: 
1-714-796- 9504 (backup fax 1 - 714-246- 5295)
or email it to IR -
Clinical- SAE@ abbvie .com.
In case of fax failure or the site does not receive confirmation of receipt of the fax, the site 
must email the report to IR -Clinical- SAE@abbvie .com.
Medical Emergency phone number: 1 -800-503- 8745
9.7.1.6 Reporting of Pregnancies Occurring During the Study
Study site personnel must report every pregnancy from the time the patient signs the ICF until 
30 days after the last dose of study treatment. W ithin 24 hours of learning of the pregnancy , 
the study site personnel must report the event to Allergen Global Drug Safety on the Clinical 
Trial Pregnancy Form and fax it to the SAE/Pregnancy fax number stated in Section 9.7.1.5 , 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 42of 74even if no AE has occurred. Pregnancies in female partners of male patients occurring during 
the time frame described above must also be reported.
The pregnancy must be f ollowed to term and the outcome reported by completing a Clinical 
Trial Pregnancy Form. If the pregnancy is associated with an SAE (e.g., if the mother is 
hospitalized for hemorrhage), a separate SAE Form for Clinical Trials must be filed as 
described in S ection 9.7.1.5 with the appropriate serious criterion (e.g., hospitalization) 
indicated in addition to the Pregnancy Form.
9.7.1.7 Potential Hy’s Law Cases
Criteria for pot ential Hy ’s Law cases are as follows:
Alanine Aminotransferase or Aspartate Aminotransferase ≥ 3x upper limit of the 
normal range (ULN) AND
Total Bilirubin ≥ 2xULN AND
Alkaline Phosphatase < 2xULN
Study site personnel must report every patient who meets these potential criteria. Typically , all 
3 analytes will be obtained from the same sample, but they may come from multiple samples 
taken within a 24 -hour period. This requirement applies from the time he or she signs the ICF 
for the trial until 30 days aft er the final protocol -defined study visit or the last known dose of 
study treatment (if the final visit does not occur).
A laboratory alert for potential Hy ’s laws cases will be in place and must notify investigators 
and the Sponsor immediately when the ab ove criteria have been met. A  potential Hy ’s law case 
must be faxed to the Sponsor on an AE of Special Interest Form as soon as possible (within 
24hours of learning of the potential Hy ’s law) to the SAE/Pregnancy fax number stated in 
Section 9.7.1.5 , even if no AE has occurred. The eCRF for potential Hy ’s law cases must be 
completed within 7 calendar days. Every effort to determine the cause of the liver enzyme 
abno rmalities must be made, and close monitoring should be initiated in conjunction with the 
medical monitor and in accordance with the FDA  “Guidance for Industry: Drug Induced 
Liver Injury -
Pre-Marketing Clinical Evaluation ” July 2009.
Medical Emergencies and Emergency Pr otocol Deviations
In medical emergencies, the invest igator will use medical judgment and remove the patient from 
immediate harm. The invest igator will then immediately notify the sponsor and the IRB 
regarding the ty pe of emergency and the cours e of action taken.
An invest igator shall notify the sponsor ’s medical safety physician and the reviewing IRB of 
any deviat ion from the invest igational plan to protect the life or phy sical well -being o f a pati ent 
in an em ergency . Such noti ce shall be given as soon as possible, but in no event later than 
5working days after the emergency occurred. Except in such an emergency , prior approval  by 
the sponsor i s requi red for any  changes in or devi ations from the protocol . All deviat ions m ust be 
docum ented on the eCRF .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 45of 749.8.2 Medical History
The patient ’s medical history  will be taken atVisits1 and 2 (Pre -Amendment 3) or V isits A  and 
B (Post -Amendment 3) and will include an account of the underlying disease state and its 
management, including CIC and current medications use.
9.8.3 Electrocardiograms
A 12-lead ECG will be recorded at screening. The investigator will evaluate the ECG tracing for 
any clinically  significant abnormalit ies.
9.8.4 Concomitant Medication Use
Patients will be queri ed at each clinic visit concerning the use of medications. Concurrent 
medicat ions used by the patients will be documented, including the name of the drug, the dose, 
the frequency , the route of administration, the date of init iation and discont inuat ion, and the 
reason for t he medication.
Guidelines for prohibited drugs listed in the inclusion/exclusion criteria (Section 9.3.2 ) are to be 
followed.
9.8.5 Anticholinergic Symptoms Questionnaire
Patients /caregivers will be asked to complete an ant icholinergic symptoms quest ionnaire at
Visits 2, 6, and 8 (Pre-Amendment 3) or V isits B, C, D, E, and F (Post -Amendment 3) . The 
questionnaire will ask patients /caregivers to describe the intensit y of any side effects that may be 
associ ated wi th the administrati on of  anticholinergic medicat ions (Appendix 5). Adverse events 
associated with the administration of anticholinergic medications detected on the 
questionnaire will be reported on the Adverse Event Form. The severity of the event and the 
relationship to the study drug will be assessed by the investigator and reported on the Adverse 
Event Form.
9.8.6 Vision Symptom Questionnaire
Post
-Amendment 3, patients/caregivers will be asked to complete a V ision Symptom 
Questionnaire at V isits B, C, D, E, and F ( Appendix 6). The questionnaire will ask 
patients/caregivers to describe any visual impairment or eye conditions for the patient.
Adverse events of vision disorders and/or symptoms detected on the V ision Sym ptom 
Questionnaire will be reported on the Adverse Event Form. The severity of the event and the 
relationship to the study drug will be assessed by the investigator and reported on the Adverse 
Event Form.
If a patient < 8 years old has started treatment an
d develops visual or ophthalmologic 
symptoms (ie, blurry vision, dry eye, dilated pupils, constant squinting, eyes drifting outward) 
it will be recommended that the patient is referred to a pediatric ophthalmologist for a 
comprehensive eye examination.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 46of 749.9 Appropriateness of Measurements
Urinary  diaries are non -invasive tools that provide a record of bladder funct ion in neurogenic and 
non-neurogenic condit ions. The data collected from these diaries give an indicat ion of urinary 
patterns and severit y of symptom s. The urinary  diary  can be used effect ively to assess 
improvement of urinary  incont inence during treatment and is an appropriate tool to use in this 
study .
Urodynamic measurements are the gold standard for evaluating bladder and sphincter function 
and for docum enting the effectiveness of new drugs and treatment paradigms. Urodynamic data 
can provide supporting evidence of changes in bladder funct ion following treatm ent wi th 
anticholinergics.
The safet y assessments, including adverse events review , physical  examinat ion, vital signs, and 
laboratory  evaluat ions represent standard evaluat ions in clinical studies evaluat ing 
anticholinergic agents. The assessment of skin eryt hema at the local applicat ion site is useful in 
determining the irritation potential o f transdermal applicat ions, like the oxybutynin topical gel.
The sparse blood sampling methodology  is appropri ate for thi s pediatri c study , to minimize the 
amount of bl ood sam pling and for the determination of average oxybutynin and 
N-desethylo xybut ynin plasma concentrati ons.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 47of 7410 QUALITY CONTROL AND ASSURANCE
The sponsor will implement and maintain qualit y control  procedures to ensure that this study  is 
conducted, and data are generated, documented, and reported in co mpliance wit h the protocol, 
GCP, and applicable regul atory  requi rements.
The sponsor or designee will routinely  conduct m onitoring and/or audi ting visits to the study  
centers to verify  the adherence to the study  protocol , the protecti on of the ri ghts and well -being 
of the patients , and the accuracy  and completeness of reported study  data recorded on the source 
docum entati on.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 48of 7411 PLANNED ST ATISTICAL METHODS
11.1 Determination of Sample Size
Sample size was calculated for the protocol as originally designed (Pre -Amendment 3: double -
blind, placebo- controlled treatm ent period followed by an open- label extension) as follows:
This study  was planned to include a minimum o f 96 pedi atric patients aged 6 to <17 years who 
have a diagnosis o f detrusor overactivit y associ ated wi th a neurol ogical condi tion. The sample 
size was selected to provide an adequate number of patients to eval uate the safet y and efficacy of 
oxybutynin chloride geltreatment in a pediatric populat ion. Patients were randomized in a 1:1 
fashio n to oxybutynin chloride gelor placebo wi thin each stratificat ion level, which were based 
on age, weight, and gender . Estimates for the average change fro m baseline (CFB) in the 
percentage of catheterizations without a leaking accident as well as the standard deviat ion for 
this variable were taken f rom oxybut ynin TDS in Study O03010. Assuming a co mmo n standard 
deviat ion of 28 for the CFB in the percentage of catheterizat ions wit hout a l eaking accident, a 
difference between treatment groups of 20 (assuming average for oxybutynin chloride gel= 25 
and average for placebo = 5), and n = 48 patients per treatment group, and then there is 93% 
power to detect a statist ically significant difference between treatment groups. Based on 
discontinuat ion rates fro m Study  O03010, if we assume a 10% dropout rate then there is 90% 
power to detect a statist ically significant difference between treatment groups.
The open -label study (patients enrolled Post -Amendment 3) will include a minimum of 
25pediatric patients aged 3 to < 17 years (efforts will be made to enroll a greater number of 
patients aged 3 years to < 6 years) who have a diagnosis of detrusor overactivity associated 
with a neurological condition. This sample size is expected to provide a minimum of 
10patients with 14 weeks of exposure.
11.2 Analysis Populations a nd Databases
Statistical analysis and data tabulat ion will be performed using data from the open -label period 
for patients enrolled after Amendment 3 and the data from the double -blind and open -label 
periods for patients enrolled prior to Amendment 3 in the following pati ent popul ations unless 
specified otherwise:
Safety popul ations:
-Post- Amendment 3 open -label safety population
-Pre-Amendment 3 double -blind safety population
-Pre-Amendment 3 open -label safety population
-Combined open -label safety pop ulation (Pre -and Post -Amendment 3)
Intent -to-treat (ITT) populations:
-Combined ITT population (Pre -and Post -Amendment 3; primary efficacy analysis 
population)
-Post- Amendment 3 ITT population
-Pre-Amendment 3 ITT population
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 49of 74Per-protocol (PP) populat ions:
-Post- Amendment 3 PP  population
-Pre-Amendment 3 PP population
PK populat ions:
-Post- Amendment 3 PK population
-Pre-Amendment 3 PK population
-Combined PK population (Pre -and Post -Amendment 3)
The Post- Amendment 3 open -label safet y popul ation is defined as all patients who receive at 
least 1dose of study treatment in the open -label peri od after Amendment 3 .
The Pre -Amendment 3 double -blind safety population is defined as all patients who receive at 
least 1 dose of study trea tment in the double -blind period before Amendment 3.
The Pre -Amendment 3 open- label safety population is defined as all patients who receive at 
least 1 dose of study treatment in the open -label period before Amendment 3.
The combined open -label safety popu lation is defined as all patients who receive at least 
1dose of study treatment in the open -label period before or after Amendment 3.
The primary  efficacy analysis populat ions will be the Post- Amendment 3 ITT population and 
thePre-Amendment 3 ITT populat ion.
The combined ITT population will include all patients who have a baseline value for the 
primary efficacy variable in the Post -Amendment 3 open- label period or all randomized 
patients who have a baseline value for the primary efficacy variable in the P re-Amendment 3 
double -blind period.
The Post- Amendment 3 ITT population will include all randomized patients who have a 
baseline value for the primary efficacy variable in the Post -Amendment 3 open- label period.
The Pre-Amendment 3 ITT populat ion will incl ude all  randomized pat ients who have a baseline 
value for the primary  efficacy  variable in the Pre -Amendment 3 double -blind period .
The Pre-Amendment 3 PP populat ion will include all patients in the Pre-Amendment 3 ITT 
popul ation who complete the double -blindtreatm ent peri od of  the study  and who are without 
significant protocol  violations.
The Post- Amendment 3 PP  population will include all patients in the Post- Amendment 3 ITT 
population who complete the Post -Amendment 3 open -label treatment period of the study and 
who are without significant protocol violations.
The PK population will include all patients who have at least 1 sam ple draw for plasma 
concentrations. The PK populat ion will only  be used in the summary  stati stics and analyses of 
the PKdata.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 50of 74Additionally , 2types o f visits are defined for the purposes of analysis and summary:
Observed cases (OC)
Last observat ion carri ed forward (LOCF)
The OC visit s are defined to be those assessment values observed at each scheduled visit. All 
applicable efficac y and safety  variables will be summarized using the OC visits.
The LOCF visit is defined as the last data recorded for each efficacy variable. This visit will be 
designated as Week 6 (LOCF). The W eek 6 (LOCF) visit will be defined for the 
Post- Amendment 3 open -label period and the Pre -Amendment 3 double -blind period and will 
only be used to summarize efficacy data. The LOCF visit provides missing value imputation for 
patients who do not complete the open -label treatment period (Post -Amendment 3) or the 
double -blind treatment period (Pre -Amendment 3) of the study  and will include all patients in 
the corresponding ITT population.
11.3 Efficacy Parameters
The primary  efficacy variable for the Post -Amendment 3 open -label period and the Pre -
Amendment 3 double -blind period will be the percentage of catheterizat ions without a leaking 
accident (continuous variable).
The fo llowing are secondary cont inuous efficacy variables that will be calculated:
Average vo lume of urine co llected per catheterization (f or Pre -Amendmen t 3 population 
only)
Average vo lume of urine co llected at first (morning awakening) catheterization 
Average number of catheterizat ions per day
The primary  efficacy endpo int for the Post -Amendment 3 open -label period and the 
Pre-Amendment 3 double -blind period is defined as the CFB to W eek 6 (LOCF) in the 
percentage of catheterizations without a leaking accident. The secondary efficacy endpo ints are 
defined as the CFB in the secondary  efficacy variables at W eek 6 (LOCF).
Baseline is V isit 2 for Pre -Amendm ent 3, and baseline is V isit B for Post -Amendment 3.
11.4 Descriptive Summaries of Efficacy Parameters
Absolute values and CFB values for all the cont inuous efficacy parameters will be summarized 
for all visits, including W eek 6 (LOCF), by  dose level (0.5, 0.75 , and 1.0 g and overall ) for the 
Post- Amendment 3 ITT and PP populations and by treatment group (placebo and oxybutynin 
chloride gel) for the Pre -Amendment 3 ITT and PP populations using descript ive statistics 
including mean, 25th percent ile, median, 75th percent ile, SD, SEM, minimum, maximum, and 
number of patients . Addit ionally , the above descriptive summaries will be provided for each age 
group ( 3 to < 6 years , 6 to < 12 years, 12 to< 17 years), for each weight category  within each
age group (≤ 18 kg an d > 18 kg for the 3 to < 6 years -of-age group, ≤ 25 kg and > 25 kg for the 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 51of 746 to < 12 years -of-age group, and ≤ 50 kg and > 50 kg for the 12 to < 17 years -of age group), and 
for each sex.
11.5 Statistical Analyses of Efficacy Parameters
All analyses will be cond ucted wi th SAS®v9.3or higher using procedures appropriate for the 
particular analysis.
11.5.1 Statistical Analysis of the Primary Efficacy Endpoint
The primary  efficacy parameter is the CFB to W eek 6 (or LOCF) in the percentage of 
catheterizations without a lea king accident. The primary efficacy parameter will be analyzed 
using an analysis o f covari ance (ANCOV A) m odel wi th the baseline measure of the primary  
variable as the covariate and treatment group and study part (Pre -Amendment 3 and 
Post- Amendment 3) as fa ctors .
To assess the effect of the study design, the primary efficacy parameter will be analyzed using 
a random effects mixed model using the combined data from the Pre -Amendment 3 double -
blind treatment period and the data from the Post- Amendment 3 open -label treatment period. 
The model will include the baseline measure and other baseline characteristics as covariates 
and treatment (Pre -Amendment 3 double -blind placebo, Pre -Amendment 3 double -blind 
oxybutynin chloride gel, Post -Amendment 3 open- label oxybu tynin chloride gel) as factors and 
will account for the heterogeneity between parts of the study (Pre -Amendment 3 vs 
Post- Amendment 3) by using a random effect for study part. If the analyses indicate 
heterogeneity , the data from the Pre -Amendment 3 double -blind treatment period and the data 
from the Post -Amendment 3 open -label treatment period will be analyzed separately . For the 
Post-Amendment 3 ITT population, the significance of the change from baseline on the 
primary efficacy measure will be assessed f rom a 2 -sided, 1 -sample t -test. For the 
Pre-Amendment 3 ITT population the primary efficacy parameter will be analyzed using an 
ANCOV A model with the baseline measure of the primary variable as the covariate and 
treatment group as factors.
11.5.2 Statistical Anal ysis of the Secondary Efficacy Endpoints
For the Post -Amendment 3 ITT population, the analyses of the secondary efficacy parameters 
will assess the CFB for each variable at Week 6 (LOCF). The significance of the change from 
baseline on the secondary effica cy measures will be assessed from 2 -sided, 1 -sample t -tests. 
For the Pre -Amendment 3 ITT population, secondary  efficacy parameters will be analyzed 
using ANCOV A models wi th the baseline m easure of the efficacy  variable as the covariate and 
treatm ent group asfactor .
11.5.3 Additional Analyses
The primary  and secondary  efficacy  endpoints will be analyzed at Week 6 LOCF) for each of 
the per -protocol populations. The analyses will be similar to those described for the primary 
and secondary efficacy endpoint analyses.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 52of 74The primary and secondary efficacy endpoints will be analyzed at each OC visit for e ach of the 
ITT and per -protocol populations. The analyses will be similar to those described for the 
primary and secondary efficacy endpoint analyses.
11.5.4 Subgroup Analyses
The primary  and secondary  efficacy  data analyses will be analyzed separately  for age groups, 
weight group, and sexgroup for each ITT population , as appropriate. Addit ionally , analysis of 
other important subgroups may be provided as well.
11.6 Safety Analysis
Safety variables will be summarized for each safety population using descript ive statist ics and 
frequency  distribut ions as defined in the fo llowing sect ions. Summaries will be provided overall 
and for each age group, weight group, and sexgroup.
11.6.1 Adverse Event s
Key results will be presented for each safety population as follows:
Post- Amendment 3 open -label safety population: by oxybutynin chloride gel dose level 
and/or overall
Pre-Amendment 3 double -blind safety population: by treatment group and/or treatment 
and dose level, and/or overall
Pre
-Amendment 3 open -label safety population: by treatment group in the lead -in 
double -blind period and overall
Combined open -label safety population: by oxybutynin chloride gel dose level and/or 
overall
The incidence of treatment -emergent adverse events will be summarized for the safet y 
popul ations as described above . Adverse events will be coded using Medical Dict ionary for 
Regulatory  Activities (MedDRA) termino logy. Summaries of the following ty pes will be 
provi ded:
Overall summary  of treatm ent-emergent adverse events
Summary  of treatm ent-emergent adverse events by MedDRA  system  organ cl ass, 
MedDRA  preferred term , study treatment relationship, and severity
Summary  of serious treatm ent-emergent adverse ev ents by MedDRA  system  organ cl ass, 
MedDRA  preferred term , study treatment relationship, and severity
Summary  of treatm ent-emergent adverse events by MedDRA  preferred term  and study
treatment relationship in descending order
Summary  of treatm ent-emergent ad verse events by MedDRA  system  organ cl ass, 
MedDRA  preferred term , and study treatment relatio nship for events leading to 
prem ature di scontinuati on from the study
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 53of 74These summaries will present the number and percentage of patients reporting an adverse event 
for each classificat ion level as well as the number of events reported. The denominators for 
calculat ing the percentages will be based on the number of patients in each safety  popul ation for 
each tabulated group.
All adverse events, SAEs , deaths, SAEs considered to be related to treatment, and adverse events 
leading to premature discontinuation fro m the study will also be provided in data list ings.
11.6.2 Extent of Exposure
Summaries for duration of exposure for each safety population will be provided by treatment
group for the Pre-Amendment 3 double -blind period, and by exposure to oxybutynin chloride 
gelfor each ofthe Pre-Amendment 3 and Post -Amendment 3 open -label periods and the 
Pre-Amendment 3 double -blind and open -label periods combined. Duration of exposure to 
study  treatment will be summarized using descriptive statist ics (mean, 25th percent ile, median, 
75thpercentile, SD, SEM, minimum, maximum, and number of patients ). Duration of exposure 
will be calculated as the difference between t he last dose date and the first dose date plus 1 day .
Addit ionally , these summaries will present the number and percentage of patients for each 
interval  (1-week m ultiples) of total  exposure. The deno minators for calculat ing the percentages 
will be based on the number of patients with exposure.
11.6.3 Laboratory Evaluations and Abnormalities
Continuous clinical laboratory  analy tes will  be summarized for each safet y popul ation by 
double -blind period treatment group, double -blind treatment/oxybutynin chloride gel sequence, 
or oxybutynin chloride gelonly, asapplicable, and by analyt e and visit using descriptive 
statist ics (mean, 25th percent ile, median, 75th percent ile, SD, SEM, minimum, maximum, and 
number of patients ). Categorical laboratory  analy tes, classified as norm al or abnorm al, will  be 
summarized for each safet y popul ation by DB treatment group or oxybutynin chloride gel only 
group as applicable, and analyte and visit using the number and percentage of patients in each 
category . The deno minators for calculat ing the percentages will be based on the number of 
patients in each treatment group or oxybutynin chloride gel only group, as applicable , with 
nonmissing assessments at a particular visit for each safet y popul ation.
Shift s to val ues outsi de of the norm al range will be presented as described above by 
summarizing the number and percentage of patients with evaluable shift s. An evaluable shift is 
one where both the baseline value (screening value) and the Pre-Amendment 3 Week 14 or 
Post-Amendment 3 W eek 14 or ETvalues are recorded. The deno minators for calculat ing the 
percentages will be based on the number of patients in each treatment group, double -blind 
treatment/ oxybutynin chloride gel sequence , or oxybutynin chloride gelonly, asapplicable
who have an ev aluable shift for a parti cular analy te. Eval uable shifts to be presented are N →L, 
N
→H, H →L, H→N, L→H, and L →N for continuous variables and normal →abnorm al for 
categori cal variables.
All clinical laboratory  values, abnormal clinical laboratory  values, and c linically significant 
laboratory  values will also be provided in data list ings.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 54of 7411.6.4 Vital Signs
Vital sign m easurements will be summarized for each safet y popul ation by treatment group, 
doubl e-blind treatment/ oxybutynin chloride gel sequence , or oxybutynin ch loride gel only 
group, as applicable , and visit using descriptive statist ics (mean, 25th percent ile, median, 75th
percent ile, SD, SEM, minimum, maximum, and number of patients ). In addit ion, descript ive 
statist ics will be presented for change fro m baseline (baseline is defined as W eek 0 [Visit 2 for 
Pre-Amendment 3 and V isit B for Post -Amendment 3] ) for systolic and diastolic blood 
pressures and heart rate.
11.6.5 Physical Examinations
Physical examinat ion assessments will be summarized for each safet y popul ation by DB 
treatm ent group or oxybutynin chloride gel only group, as applicable, and visit. For each body  
system  and assessment category , the number and percentage of patients will be presented. The 
deno minators for calculat ing the percentages will be based on the number of patients evaluated 
for each body  system .
11.6.6 Skin Assessments for Erythema
Skin assessments for ery thema will be summarized for each safet y popul ation by treatment 
group and visit for the Pre-Amendment 3 double -blind period and by oxybutynin chloride gel
only and visit for the Pre-Amendment 3 open -label period, the Pre -Amendment 3 double -blind 
and open -label periods co mbined, and the Post -Amendment 3 open-label period . Additionally , 
skin assessments for ery thema will be summarized over all visits for each of the above described 
summaries. Summaries will present the number and percentage of patients for each ery thema 
category  (none, mild, m oderate, and severe). The deno minators f or cal culat ing the percentages 
will be based on the number of patients with nonmissing assessments.
11.7 Other Assessments
11.7.1 Dem ographic and Other Pretreatment Characteristics
Patient dem ographic and physical characterist ic data andmedical history  data will be 
summarized for each analysis populat ion using descript ive statist ics (mean, 25th percentile, 
median, 75th percent ile, SD, SEM, minimum, maximum, and number of patients ) for continuous 
variables and frequency distribut ions (num ber and percentage of patients) for categorical 
variables. Patient demographic data Pre-Amendment 3 will be summarized by double -blind 
period treatm ent group and overall for the double -blind period and by oxybutynin chloride gel
only for the open -label period and double -blind and open -label periods combined. Medical 
history  data will be summarized by  double -blind period treatm ent group and overall for 
double -blind period and by oxybutynin chloride gel only for the open -label period and double -
blind and open -label periods combined. Post- Amendment 3 patient demographic and medical 
history data will be summarized by oxybutynin chloride gel level and overall.
11.7.2 Medications
Medicat ion usage will be coded using W orld Heal th Organizat ion Drug Dict ionary Enhanced 
Anat omical/Therapeut ic/Chemical classificat ion. Summaries of medicat ions will be presented 
for the safet y popul ation by anatomical and therapeutic category  and preferred name. 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 55of 74Pre-Amendment 3 , summaries for the d ouble -blind period will be provided by treatment and 
overall, and summaries for the open -label period and the double -blind and open -label periods 
combined will be provided for the oxybutynin chloride gel only group. Prior medicat ion use and 
concomitant (on or after the first day  of treatm ent) medicat ionuse will  be docum ented and 
summarized separately . If the end date of pri or medication occurs after treatment starts, then the 
medicat ion will be reported as both prior and concomitant in the summaries. Summaries for 
Post- Amendment 3 will be provided by ox ybutynin chloride gel dose level and overall.
11.7.3 Com pliance
Com pliance wi th the study treatment for each patient/visit will be calculated using the fo llowing 
formula:
Compliance =  #ofsachets dispensed − #returned
#expected  ∗100
The expected number of sachets to be used for each patient will be based on the total number of 
treatm ent days. Com pliance will  be summarized by  visit and over all visits using descript ive 
statist ics (mean, 25th percent ile, median, 75th percent ile, SD, SEM, minimum, maximum, and 
number of patients ) for the Pre-Amendment 3 double -blind safet y popul ation. Com pliance will 
be summarized for the open -label periods by visit and over all visits using the same descriptive 
statist ics.
11.7.4 Urodynamic Variables
Urodynamic variables will be summarized for the Pre-Amendment 3 double -blind and 
Post- Amendment 3 safet y popul ations. Results will be presented by treatment group and visit 
and by  treatm ent group, dose level, and visit for the Pre-Amendment 3 double -blind period and 
byoxybutynin chloride gel on ly and visit for the post -Amendment 3 open -label period using 
descript ive statistics (mean, 25th percent ile, median, 75th percentile, SD, SEM, minimum, 
maximum, and number of patients ) for continuous variables and frequency  distribut ions (number 
and percen tage of  patients ) for categori cal vari ables. Summaries will be provided overall and for 
each age group and sex. In addi tion, descriptive stati stics will be presented for change fro m 
baseline (baseline is defined as W eek 0) for continuous urodynamic variabl es.
11.7.5 Anticholinergic Symptoms Questionnaire
Anticholinergic symptom questionn aire data will be summarized for the Pre-Amendment 3 
double -blind safet y populati on by  treatm ent group and visit and by treatment group, dose level, 
and visit for the double -blind period. Anticholinergic symptom quest ionnaire data will be 
summarized by  oxybutynin chloride gel only and visi t and by oxybutynin chloride gel only, 
dose l evel, and visit for the Pre-Amendment 3 open -label period and the Pre-Amendment 3 
double -blind and open -label periods combined, and for the Post -Amendment 3 open -label 
period . Summaries will be provided overall and for each age group and sex. Summaries will 
present the number and percentage of patients for each category . The deno minators for 
calculat ing the percentages will be based on the number of patients with nonmissing values in 
each treatment group or oxybutynin chloride gel only group, or dose level and visit, as 
applicable . Addit ionally , shifts from  baseline (baseline is defined at W eek 0) for eac h quest ion 
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 56of 74will be provided for all evaluable shift s. An evaluable shift is one where both the baseline 
evaluat ion and on -treatm ent evaluat ions are recorded.
11.7.6 Vision Symptom Questionnaire
Vision symptom questionnaire data will be summarized for the Post -Amendment 3 safety 
population by visit and by dose level for the open -label period.
11.7.7 R-and S -Oxybutynin and N -desethyloxybutynin Plasma Concentrations
Plasma concentration data for oxybutynin and DEO plasma concentrations for the R -isomer, 
S-isomer, and R+S as well as the ratio of DEO to oxybutynin will be summarized for the 
pharmacokinet ic population by visit. Summaries will be provided overall and for each age group 
and sex.
Linear or nonlinear regression, as appropriate , will be used to investigate the relati onship 
between the CFB in the efficacy variables and plasma concentrations, age and plasma 
concentrations, weight and plasma concentrations, and body mass index and plasma 
concentrations for each visit.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 57of 7412 DATA HANDLING AND RECORDKEEPING
Electronic case report f orms (eCRFs) will be designed and supplied by the sponsor . The eCRFs 
represent a record of the patient ’s experience in the study . The data recorded in the eCRFs must 
be supported by  original (or source) m edical  records, as appropri ate. Data recorded d irectly on 
the eCRFs (i e, no pri or wri tten or electronic record of data) will be considered source data.
Prior to enrolling a pat ient in the study , the invest igator must review all laboratory reports used 
for screening procedures. Documentation of this rev iew must exist in the source documents 
(ie,the invest igator must sign/init ial and date the laboratory  reports, etc) to provide evidence of 
the review and to indicate the date on which the review took place. The invest igator will keep a 
log of all patients who are screened and record the reason(s) for their exclusio n. eCRFs shoul d 
be co mpleted only for patients who receive study treatment.
Com pletion and correction of eCRFs will fo llow the instructions provided by the sponsor . 
Com pleted eCRFs will be electronically signed and dated by  the invest igator .
12.1 Data Generation and Analysis
After the site personnel complete data entry , electroni c error and l ogic checks will be conducted 
to identify missing, incorrect, and/or out -of-range values. Discrepancies wi ll be resolved through 
the system .
12.2 Access to Source Documentation
The invest igator agrees that the sponsor or its designated agents, the IRB, and the FDA  or foreign 
regul atory  agencies will have reasonable access to study  source docum entati on for purposes of 
audit and review both during and after complet ion of the study . These mo nitoring visits provide 
the sponsor with the opportunit y to eval uate the progress of the study; to verify the accuracy and 
completeness of eCRFs; to assure that all protocol require ments, applicable regulat ions, and 
investigator ’s obligations are being fulfilled; and to resolve any inconsistencies in the study 
records. All participating patients will be required to signify their approval to permit inspect ion 
of their medical  records by representatives of the sponsor, the IRB, and the FDA  and/or forei gn 
regul atory  agencies, as needed.
12.3 Retention of Data
In com pliance wi th ICH gui delines, the investigator shall maintain adequate records for the 
study , including m edical  records, l aboratory  reports, consent forms, study treatment disposit ion 
records, safety  reports, inform ation regarding participants who dis continued, and other pertinent 
data. The invest igator shall maintain these records for a period of at least 2 years after the last 
approval  of a market ing applicat ion in an ICH region and unt il there are no pending or 
contem plated m arketing applicat ions in an ICH regi on, or at l east 2 y ears have el apsed since the 
formal discont inuat ion of clinical development of the study treatment. These records should be 
retained for a longer period if required by the applicable regulatory requirements or by an 
agreem ent with the sponsor . The sponsor will inform the invest igator/inst itution as to when these 
records no longer need to be retained.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 58of 7413 OTHER INFORMA TION
13.1 Financing and Insurance
Financing and insurance is addressed in a separate agreement.
13.2 Publication and Disclosur e Policy
Publicat ion and disclo sure policy is addressed in a separate agreement.
13.3 Termination of the Study
If the study  is terminated prematurely  or suspended, all  the appropriate IRB and regulatory  
authori ty (ies) will be prom ptly inform ed of the terminat ion or suspensio n and will be provided 
the reason(s) for the terminat ion or suspensio n. All obligat ions and responsibilit ies of the sponsor 
and the invest igator under GCP , the US CFR, and the Declarat ion of Helsinki will remain in 
force if the study  is term inated prematurely .
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 59of 7414 REFERENCE LIST
1.Caram elli KE, Staskin DR, Volinn W. Steady -state pharmacokinetics of an invest igational 
oxybut ynin topical gel in co mpar ison with oxybutynin transdermal system. Poster presented 
at Annual Meet ing of the American Urologica l Associ ation. May 17 -22, 2008, Orlando, FL.
2.Caram elli KE, Thom as H, Stanworth S, Hoel G. Steady -state bi oavailabilit y of oxybutynin 
topical gel  at 3 different applicat ion sites. Poster presented at Annual Meet ing of the 
American Societ y of Consul tant Phar macists. November 19 -22, 2008. New Orleans, LA.
3.Staskin DR, Dmochowski PR, Sand PK, MacDiarmid SA, Caramelli KE, Thomas H, Hoel G. 
Efficacy and safet y of oxybut ynin chloride topical gel for overactive bladder: A rando mized, 
doubl e-blind, placebo -controlled , mul ticenter study . J Urol . 2009 Apr;181:1764-1772.
4.Bauer SB. Neurogenic bladder: etio logy and assessment. Pediatr Nephrol. 2008 ;23:541 -551.
5.Franco I, Horowitz M, Grady  R. Adams RC, De Jong T, Lindert K, Albrecht D. Efficacy  and 
safet y of oxybut ynin in ch ildren wit h detrusor hy perreflexia secondary  to neurogenic bladder 
dysfunct ion. J Urol . 2005 Jan;173:221-225.
6.Aslan AR, Kogan B. Conservative management in neurogenic bladder dy sfunct ion. Curr 
Opin Urol. 2002 ;12:473 -447.
7.A Mult i-Center, Open -Label, Active -Controlled, Dose -Titration Study  Eval uating the Safet y, 
Efficacy and Pharmacokinet ics of Oxybutynin Transdermal Systems in the Treatment of 
Detrusor Overact ivity Associ ated wi th a Neurol ogical  Condi tion in Pediatric Subjects, 
Followed by a 12- Week Open -Label Safety  Extensi on Study . Watson Study  O03010, 2008.
8.Verpoorten C, Buy se G. The neurogenic bladder: medical treatment. Pediatr Nephrol 
2008 ;23:717 -725.
9.Chou FH, Ho CH, Chir MB, Lisenmeyer TA. Normal ranges of variabilit y for urodynamic 
studi es of  neurogen ic bladders in spinal cord injury. J Spinal Cord Medicine 2006 ;29:26 -31.
10.Haferkamp, A Steahler G. Gerner HJ, Dorsam J. Dosage escalat ion of intravesical 
oxybut ynin in the treatment of neurogenic bladder patients. Spinal Cord 2000 ;38:250 -254.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 60of 7415 APPENDICES
Appendix 1 Schedule of Events
Appendix 2 Clinical Laboratory Evaluations 
Appendix 3 Sample 2 -Day Urinary Diary 
Appendix 4 Urodynamic Evaluation
Appendix 5 Anticholinergic Symptoms Questionnaire
Appendix 6 Vision Symptom Questionnair e for  Parent/Car egiver
Appendix 7 Gel Application Instructions
Appendix 8 Vision Assessment Instructions for  Site
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 61of 74Appendix 1 Schedule of Events
Post- Amendment 3
Evaluation:Screening Period Open -Label Treatment Period
Visit A1Visit B Visit C Visit D Visit E Visit F/ET
-13 to-5 Days Week 0 Week 2 Week 6 Week 10 Week 14
Informed Consent X
I/ECriteria X X
Medical History X X
Vision Assessment inChildren
<8 years X2
Concomitant Medication X X X X X X
DemographicInformation X
Physical Examination X X
Height andWeight X
Vital Signs X X X X X X
12-Lead ECG X
Serum Chemistries X X
Hematology X X
UrinalysisX X3X
Urine Culture X
Urine Pregnancy Test4X X X
Urodynamics X X
Dispense 2-day Urinary Diary X X
Collect 2 -day Urinary Diary X X
Local ErythemaAssessment5X X X X
Adverse Event Assessment X X X X
Anticholinergic Questionnaire X X X X X
Vision Symptom Questionnaire X X X X X
Collect PK Sample & Record
Date/Time X X X
Dose Titration (if necessary) X
Study Treatment DispensingX6X6X X
Study Treatment Compliance X X X X
1All patients taking anticholinergic medications will be asked to discontinue treatment and complete a 3-day
washout period (11-day washout period ifthepatient waspreviously taking solifenacin).
2Vision Assessment is required prior to or at the Baseline V isit for patients < 8 years of age, at the time of
screening who have not received a vision screening assessment within the last 12 months prior to screening.
3Aurine sample foron-site urinalysis todetermine presence ofbacterial infection willbecollected.
4Urine pregnancy testwillonly beperformed forfemales ofchildbearing potential.
5Assessment forlocal erythema atapplication site
6Instruct patient/caregiver onstudy treatment application.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 62of 74Appendix 2 Clinical Laboratory Evaluations
Hematology (perf ormedonwhole blood)
Hem oglobin Mean cellvolume
Hem atocri t While blood cell(WBC) &different ial
Redblood cell(RBC) count Plateletcount
Chemistry (perf ormed onserum)
Albumin Glucose
Alanine aminotransferase (ALT) Lactate dehydrogenase (LDH)
Aspartate aminotransferase (AST) Total bilirubin
Bloodurea nitrogen (BUN) Totalprotein
Gamma glutamyl transferase (GGT) Creatinine
Sodium Chloride
Potassi um Bicarbonate
Calcium Phosphorus
Urinalysis (perform edonurine)
Ketones Protein
Specific gravit y Glucose
Potenti alforhydrogen (pH) Blood
Appearance Leukocy teesterase
Bilirubin Microscopi c examination
Other  Labs (perf ormed on urine)
Urine culture1
Urine pregnancy test2
1Atscreening only.
2Urine pregnancy testwillonly beperformed forfemales ofchildbearing potential.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 63of 74Appendix 3 Sample 2-Day Urinary Diary
Instruction to Study Coordinator:
1.Com plete thePATIENT Initials andPATIENT Number atthetopofeach diarypage AND
on the cover page, prior to providing the diary  to the study  parti cipant and/or caregiver.
2.Instruct the study  parti cipant and/or caregiver on how and when to complete the diary and to 
return the com pleted di aryat thei r next visit.
Instructions forStudy Participant and/or Caregiver:
1.Com plete the urinary  diary for 2 days in a row (Day  1 and Day 2) prior to y our next visit.
2.Begin each day of the diary with the first catheterization after waking for the day and 
continue co llecting required information unt il you/your child wake up the next morning.
3.Record the actual date for each day of thediary(day month year). Forexample:
If Day 1 is 03 Jan 2011, then Day 2 will begin wit h the first cat heterization after waking
on04Jan 2011.
4.Collect and record the actual  volume of first (morning awakening) catheterization on Day 1
and Day 2.
Use the supplied co llection container to collect and measure the urine fro m the 
first (morning awakening) catheterizat ion.
Record the volume o f urine collected with first (morning awakening) catheterizat ion in 
cubic cent imeters (cc) or milliliters (mL) in the VOLUME column of yourdiary.
5.Record thenumber ofcatheteri zationsduring theday; note: thevolume needstoberecorded
only for the first (m orning awakening) catheterizatio n.
6.Check the Yes or No box in the LEAKAGE column o f your diary, indicating if any leakage 
occurred since the last catheterization.
7.Bring thecompleted diary withyoutoyournext visit.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 64of 74Instruction to Study Coordinator upon return of diary:
1.Review the diary  entri es wi th the study  parti cipant and/or caregiver at the start of the visit.
2.If addit ional inform ation is added to the diary to clarify an entry  based on y our review, 
include this information and init ial/date y our entri es.
        
       
        
   
 
   
              
       
  
    
      
  
  
  
 
 
 
   
   
 
   
   
   
  
  
   
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 65of 74
 
   
             
       
   
   
 
 
 
   
 
  
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 66of 74Appendix 4 Urodynamic Evaluation
The fo llowing procedures outline a standard clinical urodynamic evaluat ion. The Life -Tech 
Urovi sion system  (or com parable system) with strip chart recording will be used for data 
collect ion. All equipment will be appropriately  set up and regul arly calibrated.
1.Patient will report to the urodynamic laboratory  at the scheduled t ime.
2.Inform ed wri tten consent and assent (if applicable) will be obtained from pat ient and 
parent/l egal guardi an.
3.After CIC the patient will assume the lit hotomy  posi tion and will be prepped and draped 
in a sterile fashio n.
4.All components of the urodynamic equipment will be checked for proper calibration and 
funct ion.
5.The urethra will be lubricated, and anesthetized with lidocaine jelly, as needed.
6.The patient will be catheterized wit h a triple -lumen urodynamic catheter of a size 
appropriate for the pediatric pat ient (the sm aller the better).
7.A small balloon catheter should be insert ed into the rectum to measure intra -abdo minal 
pressure.
8.The filling phase of the cystometrogram will be initiated by  infusing water or saline 
through the side -hole channel at a rate of 10 -25 mL/min in the supine or sitting position.
9. Pressure data fro m the bladder and rectal catheters will be recorded.
10.Captured urodynamic data will include:
Maximal bladder capacit y
Detrusor pressure at maximum bladder capacit y
Maximum amplitude of invo luntary detrusor contractions
Volume at first involuntary  detrus or contraction
Presence (versus total absence) of invo luntary detrusor contracti ons at > 15 cm H2O.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 67of 74Appendix 5 Anticholinergic Questionnaire

Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 68of 74

Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 69of 74

Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 70of 74Appendix 6 Vision Symptom Questionnaire for Parent/Caregiver
  
            
            
      
    
              
             
              
     
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 71of 74Appendix 7 Gel Application Instructions
The instructions below are for gel applicat ion by pati ent or caregiver:
Bathing or showering should not occur sooner than 1 hour after gel applicat ion.
If bathing before applicat ion, the area must be dried completely before gel applicat ion.
Tear open the pouch at the indentation and express the complete contents either into your 
hand or di rectly on the abdo men, upper arm/shoulder, or thigh application area (see 
diagram  on following page).
Gent ly spread the gel on the applicat ion area in a continuous line coveri ng as much of the 
applicat ion area as possible. It should be spread as uniformly and thinly as possible over 
the ent ire applicat ion area taking care not to transfer any  material to any  clothing. Care 
shoul d also be taken not to apply gel to the area in or immediately around the naval 
during the abdo minal applicat ions.
Gent ly work the gel into the skin over the entire applicat ion area unt il it dries. Do not 
continue rubbing after the gel had dried. W ithin 5 minutes after applicat ion, wash y our 
hands thorough ly wit h soap and warm water.
After applicat ion, the applicat ion site should be covered with clothing after the gel has 
dried (eg, a shirt or pants). In the event that unwashed or unclothed skin to which the gel 
has been applied co mes in direct contact with the skin of another person within a day  of 
applicat ion, the general area o f contact on the other person should be washed wit h soap 
and water as soon as possible.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 73of 74Appendix 8 Vision Assessment Instructions for Site
Visual acuity -LEA  symbols
Visual acuity is screened at a distance of 10 feet using the Lea symbols.
The child need not know these symbols, but must be able to match the indicated 
symbols on a wall chart with those on the response card.
Equipment
10' Lea V ision Ch art Student Response Card Flashcards
Table and chair
Occluder with lip
Facilities
Room approximately 15 feet long or greater , well –lit and without glare.
Procedure
Testing the right eye:
1.
The child must be standing or sitting at a table with the response card in front, eyes at 
a 10-foot distance from the chart.
2. The child must be conditioned to match symbols by pointing to the same symbol on 
the response card as is being shown with a flash card or pointed to on the chart.
3. Begin screening with one per son holding an occluder over the child's left eye.
4. Another person points to the symbols on the Lea wall chart using caution not to cover 
the rectangle line with their finger or pointer .
5. The child should point to the corresponding symbol on the response card.
6.
Start with the top line and continue downward showing one letter per line. If the child 
reaches the bottom line, show the remaining three symbols.
7. If the child misses, go to the line above and show four different symbols in that line. If 
thechild matches them correctly, proceed downward.
8. To receive credit for a line, the child must correctly match each of the four different 
symbols on the line.
9. The number recorded as the visual acuity is the smallest line the child can read 
correctly .
Testing the left eye
Cover the right eye and repeat the procedure
Age five P ASS
10/15 or better in each eye without a 2 -line difference.
Re-screen/REFER
10/20 or worse in either eye or a 2- line difference in the pass range
Age three to four P ASS
10/20 or b etter in each eye without a 2 -line difference
Re-screen/REFER
10/25 or worse in either eye or a 2- line difference in the pass range.
Oxybutynin Chloride 10% Gel AbbVie Inc.
Study: OG09002 Protocol Amendment 4 31October 2022
Confidential Page 74of 74Considerations for screening special populations:
The matching of the Lea symbols may be practiced before the screening
For some children with special needs it may be useful to reproduce the response card, 
cut and space them so that larger movements can be used when indicating the 
matching symbol.
NOTE: At recheck, the poorer eye should be screened first. Children unable to perform the 
Lea chart should be given the procedures designed for younger children. Occluders should be 
cleaned between children.
Reminders:
The detection of vision disorders and symptoms during the study will be tracked by the 
adverse event reporting process. The severity of the event and the relationship to the 
study drug will be assessed by the investigator and reported on the Adverse Event 
Form.
Any patients with asymmetric/unequal or severe refractive error will be excluded from 
the study since afor ementioned conditions can result in refractive amblyopia and may 
confound the study outcomes.
      
        
            
                          
       
               
  
   
 